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ABSTRACT 
 
Food animal species, such as cattle, sheep, goats, and pigs, are widely exhibited at stock 
shows and fairs across the United States. Animals are judged on phenotypical traits such as 
muscling, structural correctness, and frame-size. The level of competition is high, increasing the 
potential for illegal or unethical acts to gain a competitive advantage, such as doping. Anti-
doping regulation in the livestock show industry often involves drug testing. Detection of 
therapeutic drugs at very low concentrations in approved animal species raises questions about 
current anti-doping regulations in exhibition animals. Therefore, the purpose of this research was 
to identify and address data gaps in the current understanding of drug testing and drug 
disposition, and to integrate those data with published data to propose an approach to 
standardizing anti-doping policies, particularly those related to therapeutic drug use. 
To determine which drugs are most commonly identified in drug testing at livestock 
shows, a review of historical drug test results from a laboratory in Texas from 1999 to 2017 was 
performed. A total of 32,027 samples were tested during this period, of which 1,674 (5.2%) 
tested positive. Positive samples included a total of 42 different drugs and metabolites. Flunixin 
was the second most commonly identified drug.  
Currently no nonsteroidal anti-inflammatory drugs (NSAIDs) are approved by the Food 
and Drug Administration (FDA) for small ruminants, but drugs such as flunixin and meloxicam 
are used in small ruminants. Additionally, urine is the sample of choice when drug testing 
exhibition animals but there is a gap in the scientific literature describing drug concentrations in 
urine of small ruminants. Therefore, pharmacokinetic studies were performed describing plasma 
and urine concentrations of flunixin meglumine and meloxicam in goats. Drug levels in urine 
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reached peak concentrations between 8 and 12 hours after dosing for both drugs. Urine 
concentrations for both flunixin and meloxicam fell below the limit of detection (LOD) of 0.5 
ng/mL and 1 ng/mL, respectively, by 240 hours.  
Last, observed and published data, PK/PD modeling results, and measurement 
uncertainty were integrated to propose a method for establishing decision limits for therapeutic 
drugs detected in urine from animals exhibited at livestock shows. 
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NOMENCLATURE 
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NOAEL No Observed Adverse Effect Level 
NOEL No Observed Effect Level 
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PD Pharmacodynamic 
PK Pharmacokinetic 
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PO Per os (oral administration) 
TLC Thin Layer Chromatography 
TVMDL Texas A&M Veterinary Medical Diagnostic Laboratory 
USDA United States Department of Agriculture 
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CHAPTER I  
INTRODUCTION AND OVERVIEW OF CURRENT REGULATION OF DRUG USE IN 
LIVESTOCK SHOW ANIMAL SPECIES 
 
Livestock shows utilize drug testing for multiple purposes: to foster fair competition 
among competitors, to ensure animal welfare, and to protect the food supply. Ante-mortem 
samples, such as urine, blood, and feces, are screened for a variety of drugs including 
nonsteroidal anti-inflammatory drugs (NSAIDs), beta-adrenergic agonists with repartitioning 
effects, anabolic steroids, corticosteroids, stimulants, diuretics, analgesics, sedatives and 
tranquilizers, antihistamines, local anesthetics, and antibiotics. Drug testing is performed in a 
variety of show animal species including cattle, pigs, sheep, goats, horses, chickens, turkeys, and 
rabbits. 
Many shows and fairs regulate drug use with a so-called “zero tolerance” policy,1,2 
meaning any substance found in samples from an animal will result in some form of penalty for 
the exhibitor. “Zero” is defined as the lower limit of detection of the analytical technique 
employed to test samples. As analytical testing continues to improve and becomes more 
sensitive, this type of policy may become untenable and indefensible, because very low 
concentrations of drugs are unlikely to cause physiological effects. 
Drugs used in show animals can be divided into 3 categories. The first category includes 
therapeutic drugs used in a legal manner with no intention of altering performance in the animal. 
Examples include those approved by the Food and Drug Administration (FDA) to treat, control, 
or prevent disease, such as antibiotics or anthelmintics. The second category consists of drugs 
not allowed for use in animals and drugs with no therapeutic effect, used illegally to enhance 
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performance. Examples include beta-agonists in unapproved species, anabolic steroids, and illicit 
drugs, such as tetrahydrocannabinol (THC) and methamphetamine. The last category consists of 
drugs that may be used to treat, control, or prevent disease but are used illegally to enhance 
performance in animals. For example, flunixin is an NSAID indicated for the control of pyrexia 
associated with bovine and porcine respiratory diseases, endotoxemia and acute bovine mastitis 
in cattle,3 and for reducing fever associated with swine respiratory disease.4 However, it is also 
analgesic and at some concentrations can be used to mask lameness.5-7 Concentrations at which 
performance-enhancing effects of therapeutic drugs can occur are unknown in species such as 
cattle, sheep, goats, and pigs. While flunixin is approved for use in cattle and swine, many shows 
regulate the use of flunixin with a “zero tolerance” policy given its performance-enhancing 
properties. 
One unique aspect of doping in livestock show animals compared to human and equine 
sports is the added concern of food safety. Most livestock shows test urine as collection is non-
invasive, urine allows some drugs to be detected longer than is possible in plasma, and urine 
allows for the detection of major metabolites for some drugs. However, a challenge facing the 
livestock show industry is correlating urine or plasma drug concentrations with drug found in 
tissues at slaughter, also known as residues. The FDA has established tolerances, the maximum 
concentration of a drug allowed in edible tissues from food-producing animals for human 
consumption, as well as withdrawal times, the amount of time required before a food-producing 
animal or product from an animal can be harvested following drug administration. Livestock 
exhibitors confuse withdrawal time with what is often called “elimination time”, or the amount 
of time required to excrete all of a drug. In fact, the so-called elimination time is longer than the 
withdrawal time for some drugs. Therefore, following the labeled withdrawal time of a 
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medication may result in tissue concentrations below the tolerance but still result in detectable 
drug in urine. As a result, questions arise when positive urine test results are reported. Is it safe 
for an animal to enter the food supply with a positive urine test? Because the correlation between 
urine concentrations and tissue residues is mostly unknown, livestock shows choose to regulate 
some FDA approved drugs with established tolerances and withdrawal times using “zero 
tolerance”. 
Changes in drug testing methods in recent years have improved drug detection limits by 
as much as 100-fold for some drugs. Improvements in drug testing methods create the need to 
modify approaches used to regulate drug use in livestock show animal species. While a “zero 
tolerance” approach is easy to enforce and manage, it lends itself to questions that have yet to be 
answered. For example, new testing methods allow the detection of therapeutic drugs in urine 
below 0.5 parts per billion (ppb). Do these trace levels provide performance-enhancing effects in 
the animal? Another area of concern is environmental exposure to drugs. It is possible for an 
untreated animal to test positive for a drug from environmental residue contamination.8,23 An 
additional issue relates to tissue withdrawal guidelines and detection of drugs in urine. If the 
labeled withdrawal time is followed, it is possible for a drug to be detected in the urine at the 
withdrawal time. It is not clear for some drugs how much time must pass before it is no longer 
detectable in the urine. 
Therefore, the purpose of this research was to identify and address data gaps in the 
current understanding of drug testing and drug disposition, and to integrate those data with 
published data to propose an approach to standardizing anti-doping policies, particularly those 
related to therapeutic drug use. Four individual projects comprise this body of work. First, to 
determine which drugs are most commonly identified in drug testing at livestock shows, a review 
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of historical drug test results from one laboratory in Texas from 1999 to 2017 was performed. 
Second, a study was performed to describe the plasma pharmacokinetics and renal clearance of 
flunixin in goats. While there are currently no NSAIDs approved by the FDA for small 
ruminants, flunixin is used in sheep and goats as an analgesic. Additionally, urine is the sample 
of choice when testing for drugs in exhibition animals. There is currently a gap in the scientific 
literature describing concentrations of flunixin in goat urine. Third, a study was performed to 
describe the plasma pharmacokinetics and renal clearance of meloxicam in goats. Similar to 
flunixin, meloxicam is used in small ruminants and little is known about meloxicam 
concentrations in goat urine. Last, observed and published data, PK/PD modeling results, and 
measurement uncertainty were integrated to propose a method for establishing regulatory 
thresholds and decision limits for therapeutic drugs detected in urine from animals exhibited at 
livestock shows.  
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CHAPTER II 
ANALYSIS OF REPORTED DRUG TEST RESULTS FROM LIVESTOCK SHOW 
ANIMALS FROM TEXAS AND OTHER STATES IN THE UNITED STATES (1999 – 2017) 
 
Introduction 
 Doping, the use of drugs to enhance performance, is a familiar term as it applies to 
human and equine athletes. The modern era of doping dates to the early 1900s, with the illegal 
use of performance-enhancing chemicals in racehorses. Its use in the Olympics was first reported 
in 1904.9 Doping also occurs in food animal species, such as cattle, sheep, goats and pigs that are 
exhibited at livestock shows and county fairs. Media attention garnered in the show animal 
industry is significantly less than that associated with human and equine sports because most 
people do not associate the term doping with livestock show animals. 
Every year, thousands of youth across the United States (US) invest hours of time and 
energy working with animals such as cattle, sheep, goats, and pigs, preparing them for livestock 
shows and county fairs. These youth then exhibit the animals for judging at the show on 
phenotypical traits such as muscling, structural correctness, frame-size, style, and balance. 
Awards, including trophies, ribbons, belt buckles, and scholarship money, are earned by 
exhibitors whose animals place at the top of their respective class. The size of the show varies 
from local county fairs to state and national exhibitions. Regardless of size, the level of 
competitiveness is high at every show.  
An auction often follows the show where the animals are purchased by local businesses 
and individuals who desire to contribute to the scholarship funds for the youth. In some cases, 
animals can generate thousands of dollars in prize and scholarship money. For example, the 
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highest amount ever paid for a show animal was in 2001 at the Houston Livestock Show & 
Rodeo where the Grand Champion Steer was purchased at auction for $600,000.10 The level of 
competition is such that some parents and exhibitors feel compelled to perform illegal acts to 
gain an advantage over other competitors. Similar to human and equine doping, one of the more 
common methods is the use of drugs to enhance the performance of the animal. Unlike human 
and equine doping, doping in livestock show animal species creates a unique risk to food safety, 
because many of these animals end up in the food supply. 
Anti-doping regulation involves testing athletes to detect prohibited drug use. Drug 
testing in racehorses began by testing saliva in 1934.11 The first reported drug testing of human 
athletes occurred in 1966.9 Similarly, livestock shows and county fairs across the country 
implement drug testing programs to create fairness among competitors, protect animals, and 
ensure safety of the food supply chain. The Texas A&M Veterinary Medical Diagnostic 
Laboratory (TVMDL) has been providing drug testing services for county fairs and livestock 
shows across the country since 1989.  
It is important to mention that post-mortem tissue samples are subject to drug testing by 
federal regulation at the time of harvest to ensure food safety. However, comparative post-
mortem data are not available from the animals tested by TVMDL from 1999 to 2017. Ante-
mortem samples, such as urine, blood, and feces, are collected at the show and immediately 
submitted to a testing laboratory. The testing laboratory screens the samples for drugs and drug 
metabolites by a variety of methods that include thin layer chromatography (TLC), enzyme-
linked immunosorbent assay (ELISA), high performance liquid chromatography coupled with 
mass spectrometry (HPLC-MS) and gas chromatography coupled with mass spectrometry (GC-
MS). Testing laboratories screen for a variety of drugs including NSAIDs, beta-adrenergic 
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agonists with repartitioning effects, anabolic steroids, corticosteroids, stimulants, diuretics, 
analgesics, sedatives and tranquilizers, antihistamines, local anesthetics, and antibiotics. Drug 
testing is performed in a variety of show animal species including cattle, pigs, sheep, goats, 
horses, chickens, turkeys, and rabbits.  
The drug testing laboratory at TVMDL, certified by the International Organization for 
Standardization (ISO 17025), provides drug testing services for the livestock and poultry 
industries, and the horse and greyhound racing industries. TVMDL has been providing drug 
testing for the livestock show industry for approximately 27 years. Our laboratory provides drug 
testing for more than 90 shows and county fairs across 16 different states. Electronic test results 
for the last 18 years were reviewed.  
An objective of this retrospective study was to present descriptive statistics. To the 
authors’ knowledge, this is the first publication of this type data.  
Our second objective was to look for trends and to provide information to educate 
stakeholders, youth, and leaders within the livestock show industry. Changes in testing 
technology and analytical capabilities in recent years have led to detection of drugs in urine at 
much lower concentrations than ever before. It is important to share this information with 
livestock show and fair boards to allow modification of policies and procedures, and adjust to 
improvements in testing.  
Information from this study would also inform exhibitors, parents, county agents, 
agricultural science teachers, and veterinarians. Educating these stakeholders about testing 
capabilities and test results can make them aware of the ability of test methods to detect trace 
amounts of drugs. Using proper withdrawal times, avoiding use of illegal drugs, and 
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understanding the potential for an animal to be exposed to trace levels of drugs from the 
environment are all important approaches for reducing positive test results.  
Our third objective was to identify areas for potential research opportunities. Enhanced 
testing capabilities create need for better understanding of the significance of detectable drug 
presence in urine. Questions arise regarding application and relevance of low concentrations of 
drugs in urine, how they correlate with enhanced performance, and how they correlate with 
tissue levels to ensure food safety. Currently, a gap exists in the understanding of presence of a 
chemical substance and the likelihood that it provides an enhanced performance or physiologic 
effect. This drug effect or pharmacodynamics has the potential to lead to unfair competition at 
livestock shows, so correlation of detectable drug concentration with effects in animals is 
necessary. Understanding which drugs are more frequently identified in drug testing will 
establish priorities for future efforts. 
Materials & Methods 
 Drug testing data from 1999 to 2017 were queried from 2 different laboratory 
information management systems (LIMS) using Microsoft SQL Server Management Studio 
(Redmond, WA). Microsoft Access was used to format the data into a single style. Pre-
determined search criteria were utilized to filter and collect data. These criteria included test 
result (Positive/Negative), drug identified, animal species, sample matrix (e.g., urine, feces or 
retina tissue), and year. Basic statistical analyses were performed using Microsoft Excel. 
Identification of specific livestock shows was not included in order to maintain client 
confidentiality and anonymity. 
Methods used to perform drug testing included thin layer chromatography (TLC), 
enzyme-linked immunosorbent assay (ELISA), high-performance liquid chromatography 
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(HPLC), liquid chromatography – tandem mass spectrometry (LC-MS/MS), and Orbitrap™ 
liquid chromatography – high-resolution accurate mass spectrometry (LC-HRAMS). Screening 
methods included TLC, ELISA and LC-HRAMS, while confirmation methods included HPLC 
and LC-MS/MS (Table 1). 
 
Year Screening Method Confirmation Method 
1999 TLC HPLC 
2000 TLC HPLC 
2001 TLC HPLC 
2002 TLC and ELISA HPLC 
2003 TLC and ELISA HPLC 
2004 TLC and ELISA HPLC 
2005 TLC and ELISA HPLC 
2006 TLC and ELISA HPLC 
2007 TLC and ELISA LC-MS/MS 
2008 TLC and ELISA LC-MS/MS 
2009 TLC and ELISA LC-MS/MS 
2010 TLC and ELISA LC-MS/MS 
2011 TLC and ELISA LC-MS/MS 
2012 TLC and ELISA LC-MS/MS 
2013 TLC and ELISA LC-MS/MS 
2014 TLC and ELISA LC-MS/MS 
2015 LC-HRAMS LC-MS/MS 
2016 LC-HRAMS LC-MS/MS 
2017 LC-HRAMS LC-MS/MS 
 
Table 1 Methods used for screening and confirmation testing (1999 to 2017). [Thin Layer 
Chromatography (TLC), Enzyme-Linked Immunosorbent Assay (ELISA), High-Performance 
Liquid Chromatography (HPLC), Liquid Chromatography – Tandem Mass Spectrometry (LC-
MS/MS), Liquid Chromatography – High-Resolution Accurate Mass Spectrometry (LC-
HRAMS)] 
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Results 
 During 1999 to 2017, TVMDL provided drug testing for 11 to 88 shows (Figure 1). In 
2017, that included 57 from Texas and 32 outside of Texas (Figure 1). 
 
Figure 1 Number of livestock shows tested annually by the Texas A&M Veterinary Medical 
Diagnostic Laboratory (TVMDL) (1999 to 2017). 
 
Various animal matrices were submitted for drug testing in show animals (Table 2).  
Urine was the most common sample submitted. Fecal samples were submitted from chickens, 
turkeys, and rabbits. Retinal samples were submitted from cattle, pigs, sheep, and goats to detect 
beta-adrenergic agonist drugs with repartitioning effects. Liver, kidney, and muscle samples 
were submitted from cattle, sheep, goats, pigs, chickens, and turkeys. Contraband samples 
included swabs and gauze pads taken from different anatomical locations to detect the presence 
of topical medications. Samples labeled as “suspect” included those determined to be potentially 
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positive following the initial screen, but the volume of sample remaining was insufficient for 
confirmation testing. 
 
Sample Matrix Total Tested Positive Suspect 
Urine 29,238 1,525   (5.2%) 5 
Feces 1,094 44   (4.0%) 0 
Serum 842 46   (5.5%) 0 
Retina 803 57   (7.1%) 0 
Tissue (Liver, Kidney, Muscle) 50 2   (4.0%) 0 
Contraband 8 8   (100%) 0 
 
Table 2 Number of each type of sample tested, including number positive, number negative, and 
number of suspect samples (1999 to 2017). 
 
A total of 26,516 urine samples, 1,395 of which were positive (5.3%), were tested from 
cattle, sheep, goats and pigs (Figure 2): 394 of 8,149 (4.8%) cattle tested positive; 738 of 6,409 
(11.5%) swine tested positive; 116 of 5,211 (2.2%) goats tested positive; and, 145 of 6,621 
(2.2%) sheep tested positive. The highest annual number of positive samples from the 
combination of cattle, pigs, sheep, and goats was reported in 2015, during which 331 of 1,917 
(17.3%) tested positive. In 2015, 195 of 466 (41.8%) swine samples were reported positive, 
including 97 for ractopamine, 20 for caffeine, 19 for flunixin, 16 for theobromine, and 10 for 
theophylline. The total number of positive urine samples peaked in 2015, followed by a decline 
in 2016 and 2017 to 280 and 124 positive urine samples, respectively. 
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Figure 2 Percent positive urine test results by species (1999 to 2017). 
 
Fifteen (15) of 26,516 (0.06%) urine samples from cattle, sheep, goats and pigs tested 
positive for multiple drugs. Three bovine samples tested positive for both ractopamine and 
zilpaterol. One caprine sample tested positive for flunixin, lidocaine, hydroxylidocaine, 
clenbuterol, and dexamethasone. A second caprine sample tested positive for flunixin and 
ractopamine. One ovine tested positive for flunixin and methylprednisolone. Four swine samples 
tested positive for flunixin and dexamethasone. One swine sample tested positive for 
sulfamethazine and acetylsalicylic acid. One swine sample tested positive for flunixin and 
sulfamethazine. One swine sample tested positive for flunixin and methylprednisolone. One 
swine sample tested positive for dexamethasone and naproxen. One swine sample tested positive 
for flunixin, ractopamine and zilpaterol. 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
%
 P
os
iti
ve
Year
Positive Test Results
Bovine Porcine Caprine Ovine
 13 
Generally, TVMDL performs qualitative testing on samples from show animals. 
Occasionally, shows and fairs request a quantitative test to assess the concentration of a 
therapeutic drug detected in urine. While threshold levels of therapeutic drugs have not been 
established in show animal species, a quantitative test is available to determine if the 
concentration of a therapeutic drug detected in urine was low or high. From 2016 to 2017, 
TVMDL performed a quantitative test on 25 animals that tested positive for flunixin (see Figure 
3). The concentration of flunixin ranged from 0.6 to 3,600 ng/mL. 
 
 
 
Figure 3 Range of quantified urine concentrations of flunixin (2016 to 2017). (Reported as 
“Positive” in bovine, porcine, ovine, and caprine samples) (n = 25)) [inset = outliers with very 
high concentrations] 
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A total of 42 different drugs and metabolites were confirmed in urine samples from 1999 
to 2017 (Table 3). Combined, ractopamine and flunixin accounted for almost half (48.7%) of all 
positive findings in urine. 
 
Drug  Number Confirmed (1,451 Total) 
Ractopamine 490 (33.8%) 
Flunixin 252 (17.4%) 
Sulfamethazine 128 (8.8%) 
Zilpaterol 86 (5.9%) 
Dexamethasone 74 (5.1%) 
Theobromine 74 (5.1%) 
Caffeine 70 (4.8%) 
Lidocaine + Metabolites 49 (3.4%) 
Phenylbutazone + Metabolites 48 (3.3%) 
Furosemide 37 (2.6%) 
Methylprednisolone 31 (2.1%) 
Theophylline 24 (1.7%) 
Nicotine + Metabolites 24 (1.7%) 
Sulfadimethoxine 21 (1.5%) 
Acetylsalicylic acid 17 (1.2%) 
Sulfadiazine 14 (1.0%) 
Procaine 11 (0.8%) 
Firocoxib 10 (0.7%) 
Paraxanthine 9 (0.6%) 
Trimethoprim 8 (0.6%) 
Ibuprofen 7 (0.5%) 
Acepromazine + Metabolites 6 (0.4%) 
Isoflupredone 6 (0.4%) 
Chlorpromazine + Metabolites 5 (0.3%) 
Meloxicam 5 (0.3%) 
Chlortetracycline 5 (0.3%) 
Sulfamethoxazole 5 (0.3%) 
Clenbuterol 5 (0.3%) 
Boldenone 4 (0.3%) 
Naproxen 3 (0.2%) 
Diphenhydramine 3 (0.2%) 
Aminoantipyrine + Metabolites 3 (0.2%) 
Azaperone + Metabolites 2 (0.1%) 
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Dextrorphan 2 (0.1%) 
Altrenogest 2 (0.1%) 
Mepivacaine 2 (0.1%) 
Albuterol 2 (0.1%) 
Xylazine 2 (0.1%) 
Terbutaline 1 (0.07%) 
Diclofenac 1 (0.07%) 
Ketoprofen 1 (0.07%) 
Meclofenamic Acid 1 (0.07%) 
 
Table 3 Drugs confirmed in urine and number of animals confirmed positive for each drug (all 
species) (1999 to 2017). 
 
A total of 1,094 fecal samples were tested from 1999 to 2017 (Table 4). Ractopamine 
made up the majority of positive samples (88.6%; 39/44 positives) and 3.6% of total samples. 
Drug Positive 
Ractopamine 39 
Flunixin 1 
Tramadol 1 
Procaine 1 
Lidocaine 1 
Testosterone 1 
Total Tested 1,094 
 
Table 4 Drugs confirmed in feces samples from poultry species (1999 to 2017). 
 
Three beta-adrenergic agonist drugs, clenbuterol, zilpaterol, and ractopamine, were 
screened in 803 retinal samples (Table 5). Positive samples were found in 33 of 454 (7.3%) 
sheep and 9 of 267 (3.4%) goats. Ractopamine is approved by the FDA for finishing swine such 
that many shows do not consider it a banned substance in this species. The animal species was 
not provided to TVMDL for 49 of the animals, of which 3 tested positive for ractopamine. 
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Bovine 
 
Porcine 
 
Ovine 
 
Caprine 
 
Unknown 
 
Clenbuterol 
 
0 
 
0 
 
10 (2%) 
 
2 (0.7%) 
 
0 
 
Zilpaterol 
 
2 (9%) 
 
0 
 
23 (5%) 
 
5 (2%) 
 
0 
 
Ractopamine 
 
0 
 
9 (90%) 
 
0 
 
 2 (0.7%) 
 
3 (6%) 
 
Total Tested 
 
23 
 
10 
 
454 
 
267 
 
49 
 
Table 5 Drugs confirmed in retina samples from bovine, porcine, ovine, and caprine species 
(Total Number and % Positive) (1999 to 2017). 
 
Discussion 
 The data obtained during the last 19 years offers a unique look at livestock shows. While 
food safety is of highest importance, testing ante-mortem samples, such as urine, offers more 
insight into drugs used to gain a competitive edge over competition and potentially enhance the 
performance of the animal. The majority of the drugs that were confirmed in urine from cattle, 
sheep, goats, and pigs had the potential to enhance performance in the animal. TVMDL tested 
urine samples for antibiotics (sulfamethazine, sulfadiazine, sulfamethoxazole, sulfadimethoxine, 
trimethoprim, and chlortetracycline) until 2016. It is difficult to correlate detection of most 
antibiotics in urine with potential violative tissue residues, and antibiotics are not considered 
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performance-enhancing drugs. Therefore, TVMDL no longer tests for antibiotics in ante-mortem 
samples from show animals. 
Test methods used to screen livestock show samples between 1999 to 2014 included TLC 
and ELISA. Test methods used to perform confirmation testing included HPLC (1999 to 2006) 
and LC-MS/MS (2007 to 2017). In 2015, the screening method changed to LC-HRAMS. As a 
result, the capability to detect drugs at lower concentrations improved significantly. This 
coincides with a steep increase in the number of positive urine samples in cattle and pigs from 
2014 to 2015 (see Figure 2). While increased drug administration to these animals may have 
contributed to the rise in the number of positive findings, it was more likely due to the improved 
sensitivity of the new screening method. 
 Many shows and fairs regulate drug use with a so-called “zero tolerance” policy,1,2 
meaning no drug is allowed in the animal at the time of the show at any concentration. “Zero” is 
defined as the lower limit of detection of the analytical technique employed to test samples. As 
analytical testing continues to improve and becomes more sensitive, this type of policy may need 
to be reconsidered. In order to address this issue, some shows conduct investigations to 
determine the circumstances that led to a positive test result. Exhibitors found in violation are 
often times offered an opportunity to explain the details of their case in a formal appeals hearing. 
Penalties can range from withholding premiums to a lifetime ban, depending on the drug that 
was used and the circumstances surrounding the use.2 
 Regulation of drug use in show animals can be divided into 3 categories. The first 
category includes therapeutic drugs used in a legal manner with no intention of altering 
performance in the animal. Examples include those approved by the FDA to treat, control, or 
prevent disease. The second category consists of drugs not allowed for use in animals and drugs 
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with no therapeutic effect used illegally to enhance performance. Examples include beta-agonists 
in unapproved species, anabolic steroids, and illicit drugs, such as tetrahydrocannabinol (THC) 
and methamphetamine. The last category consists of therapeutic drugs used illegally to enhance 
performance in the animal. For example, flunixin is indicated for the control of pyrexia 
associated with bovine and porcine respiratory diseases, endotoxemia, and acute bovine mastitis 
in cattle,3 and for reducing fever associated with swine respiratory disease.4 However, it is also 
considered an analgesic and at certain concentrations can be used to mask lameness.5-7 
Concentrations at which performance-enhancing effects of some therapeutic drugs occur can be 
difficult to measure in species such as cattle, sheep, goats, and pigs. While flunixin is approved 
for use in cattle and swine, many shows regulate the use of flunixin with a “zero tolerance” 
policy given its performance-enhancing properties. Pharmacokinetic studies are underway to 
evaluate this policy, and to provide livestock show and fair boards the scientific data required to 
adjust or establish rules and policies regarding the use of therapeutic medications in show 
animals. 
 One unique aspect of doping in show animals compared to human and equine sports is 
the added risk to food safety. A challenge facing the livestock show industry is correlating urine 
and plasma drug concentrations with residual tissue concentrations. The FDA has established 
tolerances, the maximum concentration of a drug allowed in edible tissues from food-producing 
animals for human consumption, as well as withdrawal times, the amount of time required before 
a food-producing animal can be harvested following drug administration. Many stakeholders in 
the livestock show industry confuse withdrawal time with elimination time (i.e., the amount of 
time required to excrete all of a drug). In fact, the elimination time can be longer than the 
withdrawal time for some drugs and is highly dependent upon the sensitivity of the analytical 
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method used to detect the drug. Therefore, following the labeled withdrawal time of a medication 
will ensure tissue concentrations are below the tolerance however, it is still possible to generate a 
positive urine test. Unfortunately, the correlation between urine concentrations and tissue residue 
concentrations is generally unknown. As a result, certain FDA approved drugs with established 
tolerances and withdrawal times are regulated by “zero tolerance”. The improved sensitivity 
gained by changing the screening method in 2015 led to an increase in the number of confirmed 
positive therapeutic drugs, like flunixin, especially at lower concentrations (see Figure 3). Some 
of these low concentrations were likely the result of uncertainty in knowing how to modify 
therapeutic regimens and withdrawal times. Current research efforts are in progress to better 
understand these low concentrations, such as assessing renal clearance and elimination time, 
correlating urine concentrations with tissue concentrations for food safety, and establishing 
conservative urine withdrawal times. Hopefully, results of these studies will enable interpretation 
of laboratory results in terms of both clinical use and food safety. 
 It is also important to consider the increase in the number of positive findings in urine 
attributable to environmental substances. While caffeine and theobromine are considered 
environmental contaminants, they are stimulants that can cause changes in an animal’s 
performance and behavior, and are thus prohibited in show animals. Their psychostimulant 
properties cause psychomotor-activating, reinforcing, and arousing effects12 that can cause 
stubborn and lethargic animals to appear alert and responsive. Caffeine is also a diuretic. 
Diuretics increase the excretion of water from the body thereby accentuating muscle definition 
and body tone.13 Diuretics can act as masking agents by hastening drug removal from the body 
with increased urine production.13 As with therapeutic drugs, concentrations at which 
performance-enhancing effects can occur from drugs like caffeine and theobromine in species 
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such as cattle and pigs are unknown. The improved sensitivity due to test method changes in 
2015 also led to a significant increase in the detection of caffeine and theobromine in urine, 
especially at lower concentrations. The number of caffeine positive urine samples from 2014 to 
2015 increased from 3 to 29 in cattle and pigs combined. The number of theobromine positive 
urine samples from 2014 to 2015 increased from 2 to 21 in cattle and pigs combined. While it is 
not possible to differentiate environmental exposure from intentional administration, the 
improved sensitivity of the screening method exposed the possibility of environmental 
contamination from these drugs. 
 Testing retinal tissue provides an effective way to detect forbidden drug presence. Certain 
drugs like zilpaterol, clenbuterol, and ractopamine can remain in retina tissue for several months. 
These beta-adrenergic agonist drugs are considered repartitioning agents for their ability to 
increase feed conversion efficiency and carcass lean content. Illegal use of these drugs, 
particularly in sheep and goats, often occurs in the months leading up to competition. Carefully 
scheduled withdrawal of these drugs in advance of the show or fair increases difficulty detecting 
their presence in urine. A considerably higher percentage of sheep and goat retinal samples 
tested positive for either clenbuterol, ractopamine, or zilpaterol, compared to only 0.7% of the 
sheep and goat urine samples. 
 Fecal data were obtained from chickens, turkeys, and rabbits. Ractopamine was 
confirmed in 39 poultry animals. Topmax™ is a product that contains ractopamine hydrochloride 
and is FDA-approved for use in turkeys to improve weight gain and feed efficiency in finishing 
birds. In most cases, the distinction between chicken and turkey was not made by the show when 
the samples were submitted to TVMDL. Therefore, it is not possible to determine how many of 
the 39 positive findings were in an approved (turkey) versus unapproved (chicken) species. In 
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the US, it is illegal to administer drugs extralabel in feed. Thus, it is important to identify the 
species when making a determination about penalties for a competitor with a positive sample. 
 While violative test results garner the most attention, it is important to highlight the 
importance of the 95% of urine samples that tested negative. A positive test result can be 
damaging to a show’s reputation or the industry as a whole. The high percentage of negative test 
results from our laboratory from 1999 to 2017 is good news. As a whole, the majority of 
stakeholders involved in raising and exhibiting show animals did not participate in the illegal 
administration of performance-enhancing drugs. 
Future Directions 
People enticed to cheat to gain an advantage over their competitors will employ new 
methods and strategies to try to avoid detection. Therefore, studies on alternative test methods 
and sample types are needed to complement current methods to detect illegal drug use. For 
example, hair testing is increasingly used in other performance arenas, such as horseracing.14 
Researchers have demonstrated the ability to detect anabolic steroids and their esters in horse 
hair.15 Hair testing is also used in people to detect drugs of abuse16 and to evaluate recidivism 
before an offender of impaired driving can regain his or her driver’s license.17 The ability to 
detect illegal drug use retrospectively using hair has the ability to change the landscape of drug 
testing as a whole. Another area gaining traction in doping testing is using biomarkers indicative 
of illegal drug use, rather than testing for the actual drug.18 A biomarker refers to a quantifiable 
biological parameter that is measured and evaluated as an indicator of normal biological, 
pathogenic, or pharmacologic responses to a therapeutic intervention, as defined by the National 
Institutes of Health.19 Biomarkers are currently used by the US Anti-Doping Agency (USADA) 
to create an Athlete Biological Passport (ABP). An ABP is the monitoring of selected biological 
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parameters over time that may indirectly reveal effects of doping on the body. This approach 
allows anti-doping organizations to generate individual, longitudinal profiles for each athlete and 
to look for any fluctuations that may indicate the use of performance-enhancing drugs or 
methods.20 Biological passports are also being explored in the equine industry.21,22 
Conclusions 
 Individual animal drug test results are considered sensitive and confidential information. 
However, categorizing and reviewing the summation of test results over time provides a unique 
opportunity to make observations and identify trends. These data can be used to identify and 
prioritize drugs in need of further investigation and subsequent studies to provide a better 
understanding of the disposition of these drugs in food animal species. As testing platforms 
improve, it is important to understand how the evolution of drug testing may affect the regulation 
of drugs used in show animal species. The concentrations of flunixin quantified during 2016 to 
2017 offer an example. While some of these concentrations were quite low, it is unknown if they 
resulted in performance-enhancing effects. 
 Of the 26,390 urine samples tested between 1999 to 2017 from cattle, sheep, goats, and 
pigs, 1,393 were confirmed positive (5.3%) The annual percent positive samples from these 4 
species combined ranged from 1.1% to 17.3% during this period. The drug testing program at 
TVMDL has evolved over the last 19 years, with the most dramatic changes made in the last 3 
years. Initially, the number of drugs tested in show animals was quite small. This number has 
grown substantially, although there are likely other drugs used in show animals that we are 
unable to detect. The occurrence of positive test samples throughout these years demonstrates a 
continued need for drug testing programs in livestock show animals. 
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CHAPTER III 
PLASMA PHARMACOKINETICS AND RENAL CLEARANCE OF FLUNIXIN IN GOATS* 
 
Introduction 
 Flunixin meglumine (e.g., Banamine®) is a nonsteroidal anti-inflammatory drug 
(NSAID) indicated for alleviation of inflammation and analgesia. For example, it is used to 
control pyrexia associated with bovine and porcine respiratory diseases, endotoxemia and acute 
bovine mastitis in cattle,3 and for reducing fever associated with swine respiratory disease.4 
Flunixin works by blocking cyclooxygenase (COX), the enzyme responsible for the direct 
synthesis of prostaglandins, which are involved in inflammatory processes through their role in 
vasodilation, fever and pain. 
Flunixin is commonly used in food animals, and it is one of the more commonly detected 
drugs in exhibition animals (Table 3). While flunixin is indicated for therapeutic use, it can also 
be used to alter the performance of an animal by masking pain during competition. Regulation of 
therapeutic drugs, like flunixin, used in exhibition animals is complicated. Improvements made 
to drug testing methods in recent years make it possible for an exhibition animal treated in a 
legal manner with an approved therapeutic drug prior to competition to test positive. Low level 
exposure to some drugs can occur from environmental8,23 or feed contamination.24 Increased 
sensitivity achieved by current analytical testing platforms allows the detection of 
physiologically unimportant plasma or urine concentrations of therapeutic drugs for extended 
periods (days or weeks) after their administration.25 Because of the ability to detect very low,  
 
*Reprint of published data from Small Rumin. Res. 2019. 174:40-46. 
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insignificant concentrations of therapeutic drugs, a “zero tolerance” approach for regulation of 
therapeutic drugs, like flunixin, may be too stringent. Establishing decision limits that 
differentiate between physiologically important and unimportant concentrations of therapeutic 
drugs may be more appropriate. However, the performance-enhancing effects of NSAIDs at very 
low concentrations are unknown. 
In addition to the use of drug testing to detect unfair practices, regulation of therapeutic 
drugs used in exhibition animals is important for food safety. Once a livestock project is 
completed, the animal will enter the food supply. Exhibition animals that enter the food supply 
represent a large number of carcasses across the country. In 2004 in Texas alone, it is estimated 
that more than 14 million pounds of carcasses from livestock projects entered the food supply.26 
While the Food Safety Inspection Service (FSIS) tests tissues from carcasses for illegal drug 
residues, urine is often collected at livestock show exhibitions and tested for performance-
altering substances. Urine concentrations of flunixin have been evaluated in camels,27 pigs,28 
horses,29 dogs,30 and cattle.31 However, little is known about flunixin concentrations detected in 
urine from goats, and how these levels correlate to plasma and tissue concentrations.  
Pharmacokinetic (PK) studies are performed to evaluate the movement of a drug into, 
throughout and out of the body, that is, the time course of its absorption, bioavailability, 
distribution, metabolism, and excretion.32 These studies usually involve the collection of multiple 
plasma, urine, and in some cases tissue, samples over time. There are currently no published PK 
studies for evaluating the correlation between plasma, urine, and tissue concentrations of flunixin 
in goats. 
The legitimate use of therapeutic drugs in some animals species, like sheep and goats, 
presents a third challenge for regulating therapeutic drugs in exhibition animals. Veterinarians 
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face challenges when treating small ruminants, especially those exhibited at competitions, as 
there are currently no NSAIDs approved by the Food and Drug Administration (FDA) for small 
ruminants. Flunixin can be used extralabel only if prescribed by a licensed veterinarian in the 
context of a valid veterinarian-client-patient relationship and all other requirements of the 
Animal Medicinal Drug Use Clarification Act (AMDUCA) of 1994.33 Additionally, a tolerance 
for flunixin in goats does not exist. Thus, detection of any amount of flunixin in edible tissues 
from goats at harvest will result in a violation of federal law. This in turn can make it difficult for 
practitioners to provide guidance on meat withdrawal times to their clients. A meat withdrawal 
time for flunixin has been established for cattle and is based on an approved tolerance; however, 
veterinarians cannot use this information to estimate a withdrawal time to use in sheep and goats 
to achieve no detectable levels of flunixin in meat. 
PK studies can provide estimates of pharmacokinetic parameters, such as elimination 
half-life, that could allow regulators to modify rules about drug violations as drug testing 
platforms change. These studies can also aid veterinarians by enabling them to provide guidance 
to their livestock show clients and avoid jeopardizing their ability to exhibit an animal at the 
expense of the animal’s health. The objectives of this study were to describe plasma and urine 
PK including renal clearance of flunixin administered intramuscular in goats, to evaluate the 
effectiveness of plasma as a viable sample for drug testing in exhibition animals, and to estimate 
a conservative urine withdrawal time. 
Materials and Methods 
Animals and Housing 
Five (5) castrated male Boer goats, between 5 to 8 months old and weighing 22.2 to 36.4 
kg at the time of dosing, were used for this study. Each animal was housed in individual 
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metabolism cages. The metabolism cage dimensions (length by width by height) were as follows: 
5.5 x 2.5 x 3.5 feet and were specifically designed for small ruminant metabolism research. The 
cages were cleaned prior to the study and configured with the correct sizing of the head gates to 
allow the goats free access to water, feed, and hay. Each cage was separated by a minimum of 3 
feet. The goats were placed in the metabolism cages approximately 24 hours prior to dosing to 
allow them to acclimate. The goats were fed a commercial goat feed (Purina Mills) twice daily 
with free access to water and coastal Bermuda grass hay ad libitum throughout the study. Each 
goat received a physical examination prior to the study, and clinical examinations of all body 
systems were unremarkable, although liver and kidney function tests were not performed prior to 
the start of the study. Given that these organs are important for drug clearance, any underlying 
variability in organ function may be reflected in variability in pharmacokinetic parameter 
estimates from this study. None of the goats had any previous history of disease or prior 
exposure to NSAIDs before beginning the study. 
Drug Administration and Blood Collection 
The goats were weighed on a digital scale the morning of study commencement to 
determine the appropriate administration dose. Approximately 24 hours prior to dosing, the goats 
were restrained and sedated for intravenous catheter placement. The area where the catheter was 
inserted was clipped and scrubbed with alternating swabs of chlorhexidine and isopropyl alcohol. 
Using sterile technique, a 16 G x 3.25 in. (Angiocath™, BD, Franklin Lakes, NJ, USA) was 
inserted into the right jugular vein with an extension set and sutured to the skin using 2-0 
monofilament suture. Catheters were flushed twice daily with 6 mL of 10 units/mL heparin 
saline. A single intramuscular dose of flunixin meglumine (2.2 mg/kg; Flunixiject, 50 mg/mL, 
Henry Schein Animal Health, Dublin, OH) was administered in the lateral aspect of the cervical 
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neck on the opposite side of the jugular catheter. Injection sites were monitored daily for 
swelling. Following intramuscular administration, all goats vocalized during injection, but no 
swelling was noted at the injection site for the duration of the study. Flunixin was administered 
intramuscular as this route is anecdotally more commonly used in goats than the labeled 
intravenous route in cattle. Blood samples were taken from the jugular vein and were transferred 
to lithium heparinized tubes at 0 (pretreatment), 0.25, 0.5, 1, 2, 6, 10, 18, 36, 60, 84, 96, and 120 
hours post administration of flunixin meglumine.34 The samples were stored on ice until 
centrifugation. The samples were centrifuged at approximately 4,500 g for 10 minutes to yield 
plasma. The plasma samples were then stored at -80°C until analysis. 
Urine Collection 
Urine was collected by placing stainless steel buckets beneath the floor of the metabolism 
cages. A wire mesh was placed across the top of the buckets to prevent feces contamination of 
the urine. Urine was collected at 0 (pretreatment), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 
216, 240, 264, 288, 312, 336, and 360 hours following drug administration.34 The total volume of 
urine produced was measured and recorded at each time point. The buckets were cleaned 
between each sampling to prevent contamination and sample dilution. The pH of the urine was 
also measured and recorded at each time point using pH paper (Hydrion, Micro Essential Lab, 
Inc. Brooklyn, New York). Each urine sample represents fluid collection over time (e.g., not an 
instantaneous sample) therefore, the total amount of drug excreted at each time point was 
calculated using the total urine volume measured for each sample. Urine samples were stored at  
-80°C until analysis. 
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Postmortem Tissue Collection 
Each goat was humanely euthanized after 360 hours following sedation with xylazine 
using an intravenous dose of 1 mL/10 lbs. of pentobarbital sodium and phenytoin sodium. 
Approximately 10 grams of liver were collected from the caudal lobe on the right side of each 
goat.34 
Drug Analysis 
 Plasma and urine samples were analyzed by liquid chromatography – tandem mass 
spectrometry (LC-MS/MS) following protein precipitation.34 A reference standard for flunixin 
meglumine (purity >99%) was purchased from Sigma Aldrich. Corrections were made for the 
meglumine salt in flunixin prior to preparation of standard solutions. The LC-MS/MS method 
was validated using blank plasma and urine from goats not enrolled in the study. Plasma samples 
were thawed and extracted using a previously described method.35 Briefly, 100 μL of each 
sample was combined with 500 μL of 0.5% citric acid in acetonitrile. Samples were vortexed for 
approximately 10 seconds and then centrifuged at 4500 RPM for 5 minutes. The supernatant 
from each sample was transferred into a clean glass borosilicate (16 mm x100 mm) culture tube. 
The supernatant was then dried via Rapid Vac Evaporation at 55°C under a stream of nitrogen 
(24 psi) for approximately 15 minutes. Each sample was reconstituted in 300 μL of 50:50 
acetonitrile:deionized water (ddH2O) with 0.1% formic acid, and vortexed for approximately 30 
seconds. The samples were then filtered through a 0.2 μ PTFE Whatman Mini-uniprep syringe 
filter and analyzed by LC-MS/MS. The injection volume was 5 μL for all samples. The mobile 
phases consisted of (A) 0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile at a 
flow rate of 0.4 mL/min. A gradient was applied beginning at 30% B maintained for 1 minute, 
increasing to 90% B in 1 minute and maintained at 90% B for 1.5 minutes, followed by re-
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equilibration to 30% B for 1.5 minutes. Chromatographic separation was achieved using a BEH 
Phenyl 1.7 µm 2.1 x 100 mm column (Waters, Milford, MA) and maintained at 40°C. Flunixin 
eluted at 2.4 minutes. Calibration standards were prepared over a linear range for each sample 
matrix. The calibration solution ranged from 0.5 to 500 ng/mL for plasma and urine. The LOQ 
and LOD were determined to be 5 ng/mL and 0.5 ng/mL, respectively. The run time was 5 
minutes for each injection.  
PK Analysis 
 Drug concentrations were analyzed using commercially available software (Phoenix® 
WinNonlin® version 6.3; Certara USA, Inc., Princeton, NJ, USA) to determine PK parameters 
for each goat. Noncompartmental analysis (weighted 1/Y2) was used to determine the terminal 
rate constant (λz), half-life of the terminal phase (t1/2λ), and total area under the curve (AUC) for 
flunixin.  The maximum concentrations (Cmax) and time to maximum concentration (Tmax) in 
plasma and urine were also determined for each goat. Individual renal clearance values, 
corrected for body weight, were estimated for each goat using the following equation36: 
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝐶𝐶𝑅𝑅𝑅𝑅𝑅𝑅𝐶𝐶𝑅𝑅𝑅𝑅𝐶𝐶𝑅𝑅 �𝑚𝑚𝑚𝑚
ℎ𝐶𝐶
� = � 𝐴𝐴𝑅𝑅
𝐴𝐴𝐴𝐴𝐶𝐶
∗ 𝐵𝐵𝐵𝐵�  ; 
where Ae is the cumulative amount of drug excreted unchanged in the urine up to 360 hours, 
AUC is the area under the plasma drug concentration versus time curve to infinity, and BW is the 
body weight (kg) of each individual goat. 
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Results 
The original data was collaboratively obtained and shared between two different 
institutions. Manipulation of the data was performed independently. One form of the data has 
been reported.34 
Flunixin in Plasma 
 Median plasma flunixin concentrations over time following a single intramuscular 
injection of 2.2 mg/kg are presented in Figure 4. 
 
 
Figure 4 Plasma flunixin concentration versus time profile from 5 goats after a single 
intramuscular dose of flunixin meglumine (2.2 mg/kg). Note: Plasma data are expressed as 
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individual points; the solid line represents the mean of all goats. [Reprinted from Small Rumin. 
Res. 2019. 174:40-46.]  
 
Plasma PK variables for each goat that describe the disposition of flunixin following a 
single intramuscular injection are presented in Table 6. Flunixin concentrations in plasma were 
below the limit of quantitation (LOQ) (5 ng/mL) in 4 of 5 goats at 36 hours post drug 
administration. Plasma flunixin concentrations were below the LOQ in the 5th goat at 60 hours 
following drug administration. The median volume of distribution (Vd) (908 [627.9-2631] 
mL/kg) appears to be large however, data from intravenous administration are needed to assess 
the significance of this value. 
 32 
PK Parameter Goat 1 Goat 2 Goat 3 Goat 4 Goat 5 Mean SD Median 
r2 0.99 0.99 1.00 1.00 1.00 1.00 0.01 1.00 
Tmax (hr) 0.25 0.50 0.25 0.50 0.50 0.40 0.14 0.50 
Cmax (mcg/ml) 7.56 6.66 4.73 4.88 5.60 5.89 1.21 5.60 
λz (/hr) 0.12 0.04 0.17 0.14 0.18 0.13 0.05 0.13 
t1/2λz (hr) 5.70 15.68 4.18 5.14 3.89 6.92 4.95 5.14 
AUC0-last (hr*mcg/ml) 19.31 18.90 14.61 19.83 19.67 18.46 2.18 19.31 
AUC0-inf (hr*mcg/ml) 19.35 18.91 14.63 19.86 19.68 18.49 2.19 19.35 
AUC % Extrap (%) 0.21 0.07 0.11 0.15 0.06 0.12 0.06 0.11 
AUMC0-last (hr*mcg*mcg/ml) 68.67 90.07 59.68 71.52 64.91 70.97 11.56 68.67 
AUMC0-inf (hr*mcg*mcg/ml) 70.49 91.85 60.34 72.80 65.38 72.17 12.00 70.49 
MRTlast (hr) 3.56 4.77 4.09 3.61 3.30 3.86 0.58 3.61 
MRT0-inf (hr) 3.64 4.86 4.13 3.67 3.32 3.92 0.60 3.67 
Vd/F (ml/Kg) 935.21 2631.00 908.00 821.01 626.97 1188.04 817.61 908.00 
CL/F (ml/hr/Kg) 113.70 116.34 150.42 110.77 111.79 120.60 16.80 113.70 
 
Table 6 Plasma noncompartmental PK parameters for flunixin following administration of 2.2 mg/kg intramuscular to goats. [Tmax 
time to maximum concentration; Cmax maximum plasma concentration; AUC, area under the concentration-time curve; AUMC, area 
under the first moment-time curve; λ, slope of the terminal phase; t1/2λ, half -life of terminal phase, Vd/F, volume of distribution; 
CL/F, total body clearance]. [Reprinted from Small Rumin. Res. 2019. 174:40-46.]  
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Flunixin in Urine 
The median urine Cmax (15.5 [6.2-17.8] µg/mL) for goats administered flunixin was 
obtained around 8 hours and declined slowly until approximately 216 hours (Figure 5). 
 
 
Figure 5 Urine flunixin concentration versus time profile from 5 goats after a single 
intramuscular dose of flunixin meglumine (2.2 mg/kg). [Reprinted from Small Rumin. Res. 
2019. 174:40-46.] 
 
Individual goat PK variables in urine are presented in Table 7. Median AUC in urine was 
119.1 [101.3-364.6] μg*hr/mL.  All 5 goats had quantifiable levels of flunixin up to day 5 
following intramuscular administration, while 2 of the goats had detectable levels of flunixin on 
day 9 following drug administration. At 240 hours, the urine concentrations for all 5 goats 
dropped below the LOD (0.5 ng/mL). Renal clearance for flunixin ranged from 5.0 to 9.1 
mL/hr/kg (Table 8).
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PK Parameter Goat 1 Goat 2 Goat 3 Goat 4 Goat 5 Mean SD Median 
Tmax (hr) 8.00 8.00 8.00 8.00 8.00 8.00 0.00 8.00 
Cmax (mcg/ml) 17.78 17.19 6.19 15.47 7.16 12.76 5.63 15.47 
t1/2λz (hr) 52.64 16.85 19.36 12.95 37.91 27.94 16.81 19.36 
AUC0-inf (hr*mcg/ml) 364.55 101.33 119.11 132.94 109.67 165.52 111.88 119.11 
 
Table 7 Urine noncompartmental PK parameters for flunixin following intramuscular administration (2.2 mg/kg). [Tmax time to 
maximum concentration; Cmax maximum urine concentration; AUC, area under the concentration-time curve; t1/2λ, half -life of 
terminal phase]. [Reprinted from Small Rumin. Res. 2019. 174:40-46.]
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 Flunixin (mL/hr/kg) 
 Renal Clearance       
Component of CL/F (%)   
Goat 1 9.1 8.2   
Goat 2 5.0 4.4   
Goat 3 5.6 3.7   
Goat 4 7.1 6.1   
Goat 5 5.1 4.6   
     
     
Table 8 Renal clearance values and percent (%) contribution of renal clearance to total systemic 
clearance (CL/F) for flunixin (n = 5) following intramuscular administration of (2.2 mg/kg). 
[Mean ± SD = 6.4 ± 1.7] [Reprinted from Small Rumin. Res. 2019. 174:40-46.] 
 
Flunixin in Liver 
 Liver samples were collected at 360 hours post drug administration. Flunixin was only 
detected in the liver of goat #4 at a concentration of 8.5 ng/g. 
Discussion 
Historically, urine has been the sample of choice when drug testing exhibition animals. 
One objective of this study was to evaluate the effectiveness of plasma as a viable sample for 
drug testing exhibition animals for flunixin. Flunixin concentrations in plasma were lower than 
those measured in urine at any given time. Flunixin concentrations in plasma fell below the LOQ 
in all goats at 60 hours following drug administration, whereas flunixin concentrations in urine 
were detected for considerably longer (216 hours). Flunixin reached peak plasma concentrations 
(5.6 [4.7-7.6] µg/mL) in approximately 30 minutes, which is similar to median values reported in 
lactating dairy goats.37 The median apparent elimination half-life (5.14 [3.9-15.7] hours) is 
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similar to the mean reported in dairy goats (2.6-6.8 hours)37 and other ruminant species including 
cattle (4.48 hours),35 and sheep (3.8 hours).38 The median area under the concentration time 
curve (19.4 [14.6-19.9] μg*hr/mL) is also similar to the mean reported in dairy goats (16 
μg*hr/mL).37 One question that arises when trying to interpret the detection of flunixin in 
exhibition animals is the duration of performance-enhancing effects. Unfortunately, the 
relationship between the pharmacokinetics (e.g., plasma and urine concentrations) and 
pharmacodynamics (e.g., drug effect in the animal) of flunixin has been difficult to establish in 
food animals.37 Measurement of serum thromboxane (TXB2), a biomarker for NSAIDs exposure, 
has been performed following flunixin administration in sheep,39 goats,40 and calves.41,42 
However, urine biomarkers of flunixin exposure in food animals have not been described. Given 
that PD data for flunixin in plasma is available, and the shorter amount of time flunixin is 
detected in plasma compared to urine, plasma may provide a stronger correlation to the 
performance-altering effects of flunixin in goats. For example, the effects of flunixin 
administered to horses can persist for up to 30 hours, with maximal effects occurring between 2 
and 16 hours.43 This is one reason that regulation of flunixin in horseracing is performed using 
plasma, with the regulatory threshold level set at 20 ng/mL and a withdrawal interval of 32 
hours.44 Calves treated with flunixin as an adjunctive therapy for respiratory disease had a 
reduced respiratory rate and body temperature in as little as 6 hours, with clinical effects 
persisting for up to 24 hours.45,46 It is not likely the performance-enhancing effects of flunixin in 
goats will persist for 9 or more days, when urine concentrations can still be detected. Given that 
plasma may correlate more strongly with the performance-altering effects of flunixin in goats, 
and the LOQ and LOD in plasma and urine are equivalent, plasma is a viable sample for drug 
testing exhibition animals for flunixin. 
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Our second objective was to establish a conservative urine withdrawal time for flunixin 
administered intramuscular to goats. Taking into consideration the results of this study and the 
current “zero tolerance” policy adopted by many livestock show regulators, a conservative urine 
withdrawal time must be longer than 9 days to achieve a flunixin concentration below the LOD 
of 0.5 ng/mL. A conservative plasma withdrawal time for flunixin, administered intramuscular to 
goats, can also be obtained from the data should plasma be selected to drug test exhibition 
animals for flunixin. A conservative plasma withdrawal time must be longer than 108 hours (4.5 
days) to achieve a flunixin concentration below the LOD of 0.5 ng/mL. A calculated approach to 
estimate a withdrawal interval based on performance-altering effects will be discussed in Chapter 
V. 
Our next objective was to describe the renal clearance of intramuscular flunixin in goats. 
Renal clearance and urine flunixin concentrations in goats are affected by three main processes 
involved in renal elimination: glomerular filtration, tubular secretion, and tubular reabsorption. 
The glomerular filtration rate (GFR) in goats, as assessed by inulin clearance, is approximately 
2.2 mL/min/kg.47 The mean renal clearance for flunixin in goats reported in this study (6.4 ± 1.1 
mL/hr/kg) is lower than the mean GFR in goats. Glomerular filtration, tubular section, and 
tubular reabsorption may also contribute to differences in renal elimination of flunixin between 
species, as well as the percentage of renal contribution to systemic clearance of flunixin. While 
not examined in this study, some factors that can influence drug excretion due to GFR include 
renal blood flow and drug protein binding,47 age,48,49 and disease state.50 Elimination of many 
NSAIDs is predominantly via hepatic biotransformation. Renal excretion of unmetabolized 
NSAIDs is usually small (<5% of the dose).51 Renal clearance values reported in Table 8 were 
determined based on urine collected for more than 5 half-lives. The amount of flunixin 
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eliminated via renal excretion as a percent of the total dose administered was low, ranging from 
3.7 to 8.2%. This suggests that the primary route of elimination of flunixin in goats is via hepatic 
metabolism to more polar metabolites, such as 5-hydroxy flunixin,52 similar to camels,27 and 
horses.53 However, we did not measure metabolites in urine or feces. Systemic clearance (CL/F) 
in goats administered flunixin (120.6 ± 16.8 mL/hr/kg) is lower compared to values reported in 
cattle (150.6 ± 43.1 mL/hr/kg).35 
Our last objective was to correlate flunixin concentrations in urine and liver. Drug 
distribution in the body is affected by its binding to plasma proteins and tissue.47 The liver, one 
of the primary organs responsible for drug metabolism and elimination, is considered an edible 
tissue and is therefore a key component when assessing food safety. Regulators set tolerances for 
edible tissues to protect consumers. As discussed in Chapter I, the tolerance is the maximum 
concentration of a drug allowed in edible tissues from food-producing animals for human 
consumption. Determination of tolerances for edible tissues is performed following regulations 
established by the FDA Center for Veterinary Medicine (CVM).54 Briefly, toxicology studies are 
performed to determine the acceptable daily intake (ADI) of residues in edible tissues. The ADI 
is based on the highest dose of a drug that produces no observable effects, which can be a no-
observed-effect level (NOEL) or a no-observed-adverse-effect level (NOAEL). A safety factor, 
which reflects uncertainties associated with the extrapolation of data and information from 
toxicology studies to humans, is then applied. Additional residue chemistry studies are 
performed to measure residue depletion and identify marker residues and target tissues. The 
tolerance for flunixin in bovine liver is 125 ppb in the US (FDA) and 300 ppb in Europe 
(European Union).55 The FSIS quantitative test for flunixin in bovine liver has an LOD ≥ 62.5 
ppb.56 Only one goat (#4) had a detectable level of flunixin (8.5 ng/g) in liver upon collection at 
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360 hours post drug administration. This concentration is considerably below the US and 
European tolerances, as well as the FSIS LOD. However, flunixin is not approved for use in 
goats and thus any concentration detected in tissue by FSIS will result in a violation. Data 
describing flunixin distribution and binding to tissue in goats are limited. In some instances, 
livestock shows try to interpret and correlate drug concentrations in urine with tissue withdrawal 
times and tolerances. Because liver was only collected at one time point, it was not possible to 
assess the correlation between flunixin concentrations in urine and liver over time. Scientifically-
based recommendations regarding safe withdrawal intervals of drugs and chemicals in food-
producing animals is performed by the Food Animal Residue Avoidance Databank (FARAD), a 
component of the Food Animal Residue Avoidance & Depletion Program. The recommended 
meat withdrawal interval, provided by FARAD, in goats following intramuscular administration 
of a single dose (2.2 mg/kg) of flunixin is 15 days.57  
Finally, it appears that goat #4 is an outlier. Goat #4 had a prolonged plasma elimination 
half-life (15.7 hours) and much larger volume of distribution compared to the other goats. Goat 
#4 produced considerably less urine than the other goats over the course of sample collection. 
This animal also had a urine flunixin concentration of 224 ng/mL on day 9. This level represents 
a high concentration when compared to the quantitative flunixin data presented in Figure 3 
(Chapter II), and is unexpected considering the amount of time that passed following a single 
intramuscular dose. Additionally, goat #4 was the only goat with a detectable flunixin 
concentration in liver at 360 hours following drug administration. This outlier may have had a 
decreased rate and extent of drug absorption compared to the other goats. Bioavailability of 
intramuscular administration of flunixin has been shown to be variable in ruminants, ranging 
from 76% in cattle58 to 79% in goats.37 Second, impaired renal function could have led to 
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decreased renal clearance and reduction in urine output. Tests to monitor hepatic and renal 
function were not performed during this study, so it is not known if this goat had decreased renal 
function that may have affected the elimination rate of flunixin. 
Conclusions 
 While blood collection is more invasive than urine collection, and some food animals are 
more difficult to bleed (e.g., pigs), flunixin concentrations in plasma likely correlate more 
strongly with potential performance-enhancing effects in exhibition animals. Additionally, 
testing plasma in goats may allow a shorter conservative withdrawal time following a single 
intramuscular dose of flunixin compared to urine, as flunixin was detected for a shorter amount 
of time in plasma compared to urine. Consideration should be given to testing both plasma and 
urine in exhibition animals, similar to doping control in horseracing.44 Plasma may be better 
suited for testing for therapeutic drugs while urine offers a much longer detection time and is 
more appropriate for prohibited substances. 
 A conservative urine withdrawal time to meet current “zero tolerance” policy has been 
proposed. However, as previously mentioned, it is unlikely flunixin provides an unfair advantage 
to a goat 9 days after it was administered. Therefore, decision limits should be established for 
therapeutic drugs detected in plasma and urine from exhibition animals. Establishing decision 
limits for therapeutic drugs in exhibition animals will be discussed in Chapter V.  
The mean renal clearance for flunixin in goats reported in this study (6.4 ± 1.1 mL/hr/kg) 
is lower than the mean GFR in goats (132 mL/hr/kg).47 The amount flunixin that was eliminated 
by the kidney was small. This suggests the primary route of elimination of flunixin in goats is via 
hepatic metabolism. 
 41 
 A common question that is posed when a urine sample from a goat tests positive for 
flunixin is one about food safety and estimating tissue withdrawal time based on the urine 
concentration. From the data obtained in this study, it is not possible to make this correlation. 
Liver samples were only collected once, at the end of the study, and only one goat had a 
detectable level of flunixin in its liver. Additionally, the conservative urine and plasma 
withdrawal times proposed in this study should not be used to estimate a tissue withdrawal time 
for flunixin in goats. Additional residue chemistry studies should be performed evaluating 
flunixin concentrations in liver samples collected from goats over time to determine an 
appropriate tissue withdrawal time.  
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CHAPTER IV 
PLASMA PHARMACOKINETICS AND RENAL CLEARANCE OF MELOXICAM IN 
GOATS* 
 
Introduction 
 Meloxicam (e.g., Metacam®) is a nonsteroidal anti-inflammatory drug indicated for 
alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal 
disorders in dogs and cats.59 Meloxicam works by blocking cyclooxygenase (COX), the enzyme 
responsible for converting arachidonic acid into prostaglandin H2, the first step in the synthesis 
of prostaglandins.60 Prostaglandins, among other actions, are involved in inflammation through 
their role in vasodilation. Meloxicam has been shown to block cyclooxygenase-2 (COX-2) more 
than cyclooxygenase-1 (COX-1),61 making it desirable for treating pain and inflammation 
without the adverse effects of blocking COX-1, such as mucosal damage leading to ulceration 
throughout the gastrointestinal tract.62 
Although not labeled for food animals, meloxicam has been shown to be effective in 
treating and managing pain and inflammation in cattle,63-67 sheep,68-71 goats,72 and pigs.73 It may 
be dosed less frequently than flunixin. For example, a single subcutaneous dose of meloxicam 
has been shown to be as clinically effective as up to 3 consecutive daily intravenous doses of 
flunixin meglumine when used as an adjunctive therapy in the treatment of acute febrile 
respiratory disease in feedlot cattle.74 While meloxicam is indicated for therapeutic use, it can 
also be used to alter the performance of an animal by masking pain during competition. As  
 
*Reprint of published data from Small Rumin. Res. 2019. 174:40-46. 
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previously described in Chapters II and III, regulation of therapeutic drugs like meloxicam is 
complicated and a “zero tolerance” approach may be too stringent. 
There are currently no NSAIDs approved by the FDA for small ruminants. Meloxicam 
can be used extralabel only if prescribed by a licensed veterinarian in the context of a valid 
veterinarian-client-patient relationship and all other requirements of the Animal Medicinal Drug 
Use Clarification Act (AMDUCA) of 1994.33 Additionally, a tolerance for meloxicam in goats 
does not exist. Thus, detection of any amount of meloxicam in edible tissues from goats at 
harvest will result in a violation of federal law. While the Food Safety Inspection Service (FSIS) 
tests tissues from carcasses for illegal drug residues, urine is often collected at livestock show 
exhibitions and tested for performance-altering substances. Urine concentrations of meloxicam 
have been evaluated in horses,75 greyhounds,76 camels,77 cats,78 dogs,79 and humans.80 However, 
little is known about meloxicam concentrations detected in urine from goats, and how these 
levels correlate to plasma and tissue concentrations.  
Pharmacokinetic (PK) studies are performed to evaluate the movement of a drug into, 
throughout and out of the body, that is, the time course of its absorption, bioavailability, 
distribution, metabolism, and excretion.32 These studies usually involve the collection of multiple 
plasma, urine, and in some cases tissue, samples over time. There are currently no published PK 
studies for evaluating the correlation between plasma, urine and tissue concentrations of 
meloxicam in goats. 
PK studies provide data that allow regulators to modify rules as drug testing platforms 
change. These studies can also aid veterinarians by enabling them to provide guidance to their 
livestock show clients and avoid jeopardizing their ability to exhibit an animal at the expense of 
the animal’s health. The objectives of this study were to describe plasma and urine PK including 
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renal clearance of meloxicam administered orally in goats, to evaluate the effectiveness of 
plasma as a viable sample for drug testing in exhibition animals, and to estimate a conservative 
urine withdrawal time. 
Materials and Methods 
Animals and Housing 
Six (6) castrated male Boer goats, between 5 to 8 months old and weighing 22.2 to 36.4 
kg at the time of dosing, were used for this study. Each animal was housed in individual 
metabolism cages. The metabolism cage dimensions (length by width by height) were as follows: 
5.5 x 2.5 x 3.5 feet and were specifically designed for small ruminant metabolism research. The 
cages were cleaned prior to the study and configured with the correct sizing of the head gates to 
allow the goats free access to water, feed, and hay. Each cage was separated by a minimum of 3 
feet. The goats were placed in the metabolism cages approximately 24 hours prior to dosing to 
allow them to acclimate. The goats were fed a commercial goat feed (Purina Mills) twice daily 
with free access to water and coastal Bermuda grass hay ad libitum throughout the study. Each 
goat received a physical examination prior to the study, and clinical examinations of all body 
systems were unremarkable, although liver and kidney function tests were not performed prior to 
the start of the study. Given that these organs are important for drug clearance, any underlying 
variability in organ function may be reflected in variability in pharmacokinetic parameter 
estimates from this study. None of the goats had any previous history of disease or prior 
exposure to NSAIDs before beginning the study. 
Drug Administration and Blood Collection 
The goats were weighed on a digital scale the morning of study commencement to 
determine the appropriate administration dose. Approximately 24 hours prior to dosing, the goats 
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were restrained and sedated for intravenous catheter placement. The area where the catheter was 
inserted was clipped and scrubbed with alternating swabs of chlorhexidine and isopropyl alcohol. 
Using sterile technique, a 16 G x 3.25 in. (Angiocath™, BD, Franklin Lakes, NJ, USA) was 
inserted into the right jugular vein with an extension set and sutured to the skin using 2-0 
monofilament suture. Catheters were flushed twice daily with 6 mL of 10 units/mL heparin 
saline. An oral dose of meloxicam (0.5 mg/kg; 15 mg tablets, Cipla USA Inc., Sunrise, FL) was 
administered to each goat per the labeled instructions. The meloxicam tablets were dissolved in 5 
mL of water and administered using a 60 mL catheter tipped syringe. Blood samples were taken 
from the jugular vein and were transferred to lithium heparinized tubes at 0 (pretreatment), 0.25, 
0.5, 1, 2, 6, 10, 18, 36, 60, 84, 96, 120, 132, 144, 156, 180, 204, and 228 hours post 
administration of meloxicam.34 The samples were stored on ice until centrifugation. The samples 
were centrifuged at approximately 4,500 g for 10 minutes to yield plasma. The plasma samples 
were then stored at -80°C until analysis. 
Urine Collection 
Urine was collected by placing stainless steel buckets beneath the floor of the metabolism 
cages. A wire mesh was placed across the top of the buckets to prevent feces contamination of 
the urine. Urine was collected at 0 (pretreatment), 4, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 
216, 240, 264, 288, 312, 336, and 360 hours following drug administration.34 The total volume of 
urine produced was measured and recorded at each time point. The buckets were cleaned 
between each sampling to prevent contamination and sample dilution. The pH of the urine was 
also measured and recorded at each time point using pH paper (Hydrion, Micro Essential Lab, 
Inc. Brooklyn, New York). Each urine sample represents fluid collection over time (e.g., not an 
instantaneous sample) therefore, the total amount of drug excreted at each time point was 
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calculated using the total urine volume measured for each sample. Urine samples were stored at  
-80°C until analysis. 
Postmortem Tissue Collection 
Each goat was humanely euthanized after 360 hours following sedation with xylazine 
using an intravenous dose of 1 mL/10 lbs. of pentobarbital sodium and phenytoin sodium. 
Approximately 10 grams of liver were collected from the caudal lobe on the right side of each 
goat.34 Samples were stored at -80°C until analysis. 
Drug Analysis 
Plasma and urine samples were analyzed by liquid chromatography – tandem mass 
spectrometry (LC-MS/MS) following protein precipitation.34 A reference standard for 
meloxicam (purity >99%) was purchased from Sigma Aldrich. The LC-MS/MS method was 
validated using blank plasma and urine from goats not enrolled in the study. Plasma samples 
were thawed and extracted using a previously described method.35 Briefly, 100 μL of each 
sample was combined with 500 μL of 0.5% citric acid in acetonitrile. Samples were vortexed for 
approximately 10 seconds and then centrifuged at 4500 RPM for 5 minutes. The supernatant 
from each sample was transferred into a clean glass borosilicate (16 mm x100 mm) culture tube. 
The supernatant was then dried via Rapid Vac Evaporation at 55°C under a stream of nitrogen 
(24 psi) for approximately 15 minutes. Each sample was reconstituted in 300 μL of 50:50 
acetonitrile:deionized water (ddH2O) with 0.1% formic acid, and vortexed for approximately 30 
seconds. The samples were then filtered through a 0.2 μ PTFE Whatman Mini-uniprep syringe 
filter and analyzed by LC-MS/MS. The injection volume was 5 μL for all samples. The mobile 
phases consisted of (A) 0.1% formic acid in water and (B) 0.1% formic acid in acetonitrile at a 
flow rate of 0.4 mL/min. A gradient was applied beginning at 35% B increasing to 90% B in 1 
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minute, maintained at 90% B for 1.1 minutes, followed by re-equilibration to 35% B for 1.5 
minutes. Chromatographic separation was achieved using an HSS 1.8 µm 2.1 x 100 mm column 
(Waters, Milford, MA) and maintained at 40°C. Meloxicam eluted at 2.38 minutes. Calibration 
standards were prepared over a linear range for each sample matrix. The calibration solution 
ranged from 0.5 to 500 ng/mL for plasma and urine. The LOQ and LOD were determined to be 5 
ng/mL and 1 ng/mL, respectively. The run time was 5 minutes for each injection. 
PK Analysis 
 Drug concentrations were analyzed using commercially available software (Phoenix® 
WinNonlin® version 6.3; Certara USA, Inc., Princeton, NJ, USA) to determine PK parameters 
for each goat. Noncompartmental analysis (weighted 1/Y2) was used to determine the terminal 
rate constant (λz), half-life of the terminal phase (t1/2λ), and total area under the curve (AUC) for 
meloxicam (PO).  The maximum concentrations (Cmax) and time to maximum concentration 
(Tmax) in plasma and urine were also determined for each goat. Individual renal clearance values, 
corrected for body weight, were estimated for each goat using the following equation36: 
𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 𝐶𝐶𝑅𝑅𝑅𝑅𝑅𝑅𝐶𝐶𝑅𝑅𝑅𝑅𝐶𝐶𝑅𝑅 (𝑚𝑚𝑚𝑚/ℎ𝐶𝐶)  = � 𝐴𝐴𝐴𝐴
𝐴𝐴𝐴𝐴𝐴𝐴
∗ 𝐵𝐵𝐵𝐵� ; 
where Ae is the cumulative amount of drug excreted unchanged in the urine up to 360 hours, 
AUC is the area under the plasma drug concentration versus time curve to infinity, and BW is the 
body weight (kg) of each individual goat. 
Results 
 The original data was collaboratively obtained and shared between two different 
institutions. Manipulation of the data was performed independently. One form of the data has 
been reported.34 
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Meloxicam in Plasma 
Median plasma meloxicam concentrations over time following a single oral dose of 0.5 
mg/kg are presented in Figure 6.   
 
 
Figure 6 Plasma meloxicam concentration versus time profile from 6 goats after a single oral 
dose of meloxicam (0.5 mg/kg). Note: Plasma data are expressed as individual points; the solid 
line represents the mean of all goats. [Reprinted from Small Rumin. Res. 2019. 174:40-46.] 
 
Individual plasma PK parameters for goats administered meloxicam are presented in 
Table 9. Meloxicam plasma concentrations after oral administration fell below 0.01 µg/mL after 
150 hours in all 6 goats. 
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PK Parameter Goat 1 Goat 2 Goat 3 Goat 4 Goat 5 Goat 6 Mean SD Median 
r2 0.99 1.00 1.00 0.97 1.00  0.99 0.01 1.00 
Tmax (hr) 6.00 10.00 6.00 6.00 18.00 6.00 8.67 4.84 6.00 
Cmax (mcg/ml) 0.37 0.27 0.63 0.77 0.99 0.88 0.65 0.28 0.70 
λz (/hr) 0.10 0.08 0.07 0.02 0.02  0.06 0.04 0.07 
t1/2λz (hr) 7.04 9.17 9.55 39.33 32.82  19.58 15.26 9.55 
AUC0-last (hr*mcg/ml) 8.59 7.30 14.91 23.12 33.12 20.39 17.91 9.73 17.65 
AUC0-inf (hr*mcg/ml) 8.66 7.33 14.95 23.25 33.36  17.51 10.87 14.95 
AUC % Extrap (%) 0.70 0.36 0.28 0.54 0.71  0.52 0.20 0.54 
AUMC0-last (hr*mcg*mcg/ml) 145.71 132.63 247.61 523.25 869.58 383.95 383.79 280.62 315.78 
AUMC0-inf (hr*mcg*mcg/ml) 149.98 135.20 251.66 549.81 917.72  400.87 333.58 251.66 
MRTlast (hr) 16.95 18.17 16.61 22.63 26.26 18.83 19.91 3.78 18.50 
MRT0-inf (hr) 17.33 18.45 16.83 23.65 27.51  20.75 4.65 18.45 
Vd/F (ml/Kg) 586.52 903.36 460.72 1220.38 709.72  776.14 297.23 709.72 
CL/F (ml/hr/Kg) 57.77 68.25 33.44 21.51 14.99  39.19 23.03 33.44 
 
Table 9 Plasma noncompartmental PK parameters for meloxicam following oral administration (0.5 mg/kg). [Tmax time to maximum 
concentration; Cmax maximum plasma concentration; AUC, area under the concentration-time curve; AUMC, area under the first 
moment-time curve; λ, slope of the terminal phase; t1/2λ, half -life of terminal phase, Vd/F, volume of distribution; CL/F, total body 
clearance] [Reprinted from Small Rumin. Res. 2019. 174:40-46.]
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Meloxicam in Urine 
 Individual urine PK parameters for goats administered meloxicam are presented in Table 
10. Urine concentrations for goats administered meloxicam were first detected in urine by 4 
hours post dose (Figure 7). After 100 hours, all urine samples fell below 100 ng/mL and at 216 
hours, meloxicam concentrations in urine from all 6 goats were below the LOD. One goat had 
considerably lower urine output, which was likely the reason for prolonged drug detection. The 
median terminal elimination half-life in urine was 35.82 [15.4-58.2] hours.  
 
 
Figure 7 Urine meloxicam concentration versus time profile from 6 goats following oral 
administration of meloxicam (0.5 mg/kg). [Reprinted from Small Rumin. Res. 2019. 174:40-46.] 
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Renal clearance for meloxicam ranged from 0.2 to 2.0 mL/hr/kg and percent contribution 
of renal clearance to total clearance was low, ranging from 1.0 to 5.0% (Table 10). 
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PK Parameter Goat 1 Goat 2 Goat 3 Goat 4 Goat 5 Goat 6 Mean SD Median 
Tmax (hr) 12.00 12.00 24.00 24.00 12.00 12.00 16.00 6.20 12.00 
Cmax (mcg/ml) 0.41 0.74 0.73 0.26 0.31 0.97 0.57 0.28 0.57 
t1/2λz (hr) 58.21 34.08 29.55 15.41 37.56 38.00 35.47 13.91 35.82 
AUC0-inf (hr*mcg/ml) 16.42 26.38 30.33 13.65 12.19 23.88 20.48 7.42 20.15 
 
Table 10 Urine noncompartmental PK parameters for meloxicam following oral administration (0.5 mg/kg). [Tmax time to maximum 
concentration; Cmax maximum urine concentration; AUC, area under the concentration-time curve; t1/2λ, half -life of terminal phase] 
[Reprinted from Small Rumin. Res. 2019. 174:40-46.]
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                            Meloxicam 
                 (mL/hr/kg)                 
Renal Clearance       
component of CL/F (%) 
   Goat 1                     0.2                   1.0 
   Goat 2                     2.0                   2.9 
   Goat 3                     0.5                   3.1 
   Goat 4                     0.5                   1.5 
   Goat 5                     1.1                   5.0 
   Goat 6                     1.5                   2.6 
  
Table 11 Renal clearance values and percent (%) contribution of renal clearance to total systemic 
clearance (CL/F) for meloxicam (n = 6) following oral administration of (0.5 mg/kg). [Mean ± 
SD = 1.0 ± 0.7] [Reprinted from Small Rumin. Res. 2019. 174:40-46.] 
 
Meloxicam in Liver 
Meloxicam was not detected in the liver in 2 of 6 goats at 336 hours. Three (3) goats had 
detectable levels of meloxicam (1.4, 1.8, and 1.5 ng/g) in liver upon collection at 360 hours post 
drug administration. 
Discussion 
Historically, urine has been the sample of choice when drug testing exhibition animals. 
One objective of this study was to evaluate the effectiveness of plasma as a viable sample for 
drug testing exhibition animals for meloxicam. The median Cmax for meloxicam was similar 
between plasma (0.7 [0.27-0.99] µg/mL) and urine (0.57 [0.26-0.97] µg/mL). Plasma 
concentrations of meloxicam were below the LOD (1 ng/mL) in all goats at 180 hours (7.5 days) 
post drug administration. Urine concentrations of meloxicam were below the LOD in all goats at 
216 hours (9 days) post drug administration. Similar to flunixin, one question that arises when 
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trying to interpret the detection of meloxicam in exhibition animals is the duration of 
performance-enhancing effects. The relationship between the pharmacokinetics (e.g., plasma and 
urine concentrations) and pharmacodynamics (e.g., drug effect in the animal) of meloxicam in 
food animals is not well described. Measurement of serum thromboxane (TXB2) has been 
performed following meloxicam administration in piglets.81 However, urine biomarkers of 
meloxicam exposure in food animals have not been described. The efficacy of meloxicam in 
horses has been shown to last for several days. For example, the effects of meloxicam 
administered to horses following orthopedic surgery persisted for 6 days, following daily dosing 
for 5 days.82 Meloxicam has also been shown to significantly reduce the display of painful 
behaviors and physiological responses to pain in band castrated and surgical castrated calves for 
up to 72 hours following a single oral treatment.83 It is unlikely the performance-enhancing 
effect of meloxicam in goats will persist for 8 days following a single oral dose, when urine 
concentrations can still be detected. Therefore, plasma may correlate more strongly to the 
performance-altering effects of meloxicam in goats, given the shorter amount of time meloxicam 
is detected in plasma compared to urine. Given that plasma may correlate more strongly to the 
performance-altering effects of meloxicam in goats, and the LOQ and LOD in plasma and urine 
are equivalent, plasma is a viable sample for drug testing exhibition animals for meloxicam. 
Our second objective was to establish a conservative urine withdrawal time for 
meloxicam administered orally to goats. Taking into consideration the results of this study and 
the current “zero tolerance” policy adopted by many livestock show regulators, a conservative 
urine withdrawal time must be longer than 8 days to achieve a meloxicam concentration below 
the LOD of 1 ng/mL. A conservative plasma withdrawal time for meloxicam administered orally 
to goats can also be obtained from the data, should plasma be selected to drug test exhibition 
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animals for meloxicam. A conservative plasma withdrawal time must be longer than 156 hours 
(6.5 days) to achieve a meloxicam concentration below the LOD of 0.5 ng/mL. A calculated 
approach to estimate a withdrawal interval based on performance-altering effects will be 
discussed in Chapter V. 
Our next objective was to describe the renal clearance of oral meloxicam in goats. Renal 
clearance and urine meloxicam concentrations in goats are affected by three main processes 
involved in renal elimination: glomerular filtration, tubular secretion, and tubular reabsorption. 
The glomerular filtration rate (GFR) in goats, as assessed by inulin clearance, is approximately 
2.2 mL/min/kg.47 The mean renal clearance for meloxicam in goats reported in this study (1.0 ± 
0.7 mL/hr/kg) is lower than the mean GFR in goats. Glomerular filtration, tubular section, and 
tubular reabsorption may also contribute to differences in renal elimination of meloxicam 
between species, as well as the percentage of renal contribution to systemic clearance of 
meloxicam. While not examined in this study, some factors that can influence drug excretion due 
to GFR include renal blood flow and drug protein binding,47 age,48,49 and disease state.50 
Elimination of many NSAIDs is predominantly via hepatic biotransformation. Renal excretion of 
unmetabolized NSAIDs is usually small (<5% of the dose).51 Renal clearance values reported in 
Table 11 were determined based on urine collected for more than 5 half-lives. The amount of 
meloxicam eliminated via renal excretion as a percent of the total dose administered was low, 
ranging from 0.9 to 4.6%. This suggests that the primary route of elimination of meloxicam in 
goats is via hepatic metabolism to more polar metabolites, such as 5’-hydroxymethylmeloxicam 
and 5’-carboxymeloxicam, similar to rats,84,85 mice,85 mini-pigs,85 humans,85,86 and horses.87-89 
However, we did not measure metabolites in urine or feces. 
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Our last objective was to correlate meloxicam concentrations in urine and liver. Drug 
distribution in the body is affected by its binding to plasma proteins and tissue.47 The liver, one 
of the primary organs responsible for drug metabolism and elimination, is considered an edible 
tissue and is therefore a key component when assessing food safety. Regulators set tolerances for 
edible tissues to protect consumers.54 As discussed in Chapter I, the tolerance is the maximum 
concentration of a drug allowed in edible tissues from food-producing animals for human 
consumption. A tolerance for meloxicam has not been established in edible tissues for goats. The 
FSIS quantitative test for meloxicam in bovine kidney and muscle has an LOD ≥ 10 ppb.56 Three 
(3) goats had detectable levels of meloxicam (1.4, 1.8, and 1.5 ng/g) in liver upon collection at 
360 hours post drug administration. This concentration is considerably below the FSIS LOD for 
meloxicam in bovine kidney and muscle. However, meloxicam is not approved for use in goats 
and thus any concentration detected in tissue by FSIS will result in a violation. Data describing 
meloxicam distribution and binding to tissue in goats are limited. In some instances, livestock 
shows try to interpret and correlate drug concentrations in urine with tissue withdrawal times and 
tolerances. Because liver was only collected at one time point, it was not possible to assess the 
correlation between meloxicam concentrations in urine and liver over time.  
Conclusions 
Similar to flunixin, meloxicam concentrations in plasma likely correlate more strongly 
with potential performance-enhancing effects in exhibition animals. Additionally, testing plasma 
in goats may allow a shorter conservative withdrawal time following a single oral dose of 
meloxicam compared to urine, as meloxicam was detected for a shorter amount of time in plasma 
compared to urine. However, consideration should be given to testing both plasma and urine in 
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exhibition animals. Plasma may be better suited for testing for therapeutic drugs, but urine is 
likely more appropriate for prohibited substances. 
 A conservative urine withdrawal time of longer than 8 days is necessary to meet current 
“zero tolerance” regulations. However, as previously mentioned, it is unlikely meloxicam 
provides an unfair advantage to a goat 8 days after it was administered. 
The mean renal clearance for meloxicam in goats reported in this study (1.0 ± 0.7 
mL/hr/kg) is lower than the mean GFR in goats (132 mL/hr/kg).47 The amount of meloxicam that 
was eliminated by the kidney was small. This suggests the primary route of elimination of 
meloxicam in goats is via hepatic metabolism. 
 It was not possible to make a correlation between urine and tissue concentrations of 
meloxicam. Liver samples were only collected once, at the end of the study, and while three 
goats had detectable levels of meloxicam in liver, the levels were quite low. Therefore, the 
conservative urine and plasma withdrawal times proposed in this study should not be used to 
estimate a tissue withdrawal time for meloxicam in goats.  
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CHAPTER V 
INTEGRATION OF OBSERVED AND PUBLISHED DATA, PK/PD CONCEPTS, AND 
MEASUREMENT UNCERTAINTY TO PROPOSE A METHOD FOR ESTABLISHING 
DECISION LIMITS FOR THERAPEUTIC DRUGS DETECTED IN ANIMALS EXHIBITED 
AT LIVESTOCK SHOWS 
 
Introduction to the Problem 
 Testing for drugs that have the ability to enhance performance in competition animals is 
common practice. For example, drug testing is performed in many different animal competitions 
that include: Quarter Horse, Thoroughbred, and Standardbred (harness) racing; equestrian events 
including dressage, jumping, draft horse showing, trail riding, cutting, and reigning; greyhound 
racing; camel racing; pigeon racing; and dog pulling/sledding. Another animal industry that 
utilizes drug testing is the livestock show industry. Similar to other performance animal 
competitions, livestock shows utilize drug testing to foster fair competition among competitors 
and ensure animal welfare. Ante-mortem samples, such as urine, blood, and feces are tested for a 
variety of drugs that are considered to have the ability to enhance performance in livestock. 
These drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), beta-adrenergic agonist 
drugs with repartitioning effects, analgesics, stimulants, sedatives and tranquilizers, 
antihistamines, and illicit drugs. 
Testing livestock exhibited at shows for drugs is more complex than the other 
performance animal competitions, however. Unlike other performance animal competitions, a 
rationale for drug testing of exhibited livestock is to ensure food safety. In addition to testing 
ante-mortem samples for performance-enhancing drugs, post-mortem samples from exhibited 
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livestock also are tested to protect the food supply. Once a livestock project is completed, the 
animal will enter the food supply. Exhibition animals that enter the food supply represent a large 
number of carcasses across the country. In 2004 in Texas alone, it is estimated that more than 14 
million pounds of carcasses from livestock projects entered the food supply.26 Post-mortem 
samples, such as liver, kidney, and muscle are screened for a variety of drugs that include 
NSAIDs, beta-adrenergic agonists with repartitioning effects, and antibiotics. 
 Also unique to livestock shows compared to other performance animal competitions is 
how drug testing is regulated. Regulation of drugs detected in post-mortem samples from 
exhibition animals is under the purview of the Food and Drug Administration (FDA) and the 
United States Department of Agriculture (USDA) Food Safety Inspection Service (FSIS). The 
FDA approves tolerances and withdrawal times for meat and other edible tissue as part of 
approval of drugs for use in food animals. The tolerance is the maximum concentration of a drug 
allowed in edible tissues from food-producing animals for human consumption, and withdrawal 
time is the amount of time before a food-producing animal can be harvested following drug 
administration. Regulation of drugs detected in ante-mortem samples from exhibition animals is 
under the purview of the board of directors of the individual livestock show or fair, and usually 
involves a so-called “zero tolerance” policy.1,2 Regulation of drugs detected in ante-mortem 
samples can be divided into 2 categories: 1) prohibited substances, and 2) drugs that are 
administered in a legal manner. While “zero tolerance” is appropriate for prohibited substances, 
thresholds and decision limits should be established for drugs administered legally.  
Establishing decision limits for drugs administered legally to exhibition animals, such as 
therapeutic drugs like NSAIDs, is a novel approach for regulating drug testing of ante-mortem 
samples in the livestock show industry. Determination of decision limits should be based on 
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pharmacokinetics, drug disposition and metabolism in the body, and pharmacodynamics, the 
drug’s effect on the body. Establishing a numerical decision-point to classify a sample as being 
negative or positive also must account for measurement error, and intra- and inter-individual 
variance.  
Currently, the difference between a sample testing positive or negative is determined by 
the limit of detection of the analytical assay. In other words, if the analytical instrument can 
detect the presence of a drug in a sample, the sample is deemed positive. Changes in analytical 
testing methods in recent years have lowered the limit of detection for drugs used in a legal 
manner. This has increased the number of positive tests, raising concerns about the policy of 
“zero tolerance”. 
Current analytical instrumentation used for drug testing allows the detection of ‘trace’ 
amounts of chemical substances, including therapeutic drugs. A ‘trace’ level can be defined as a 
pharmacologically-insignificant concentration, or the “Highest No Effect Dose” (HNED).90 Most 
drug testing laboratories in the US that test samples from exhibited livestock also perform drug 
testing for the horse racing industry. They must use highly sensitive analytical instruments to 
detect therapeutic drugs that have very low regulatory threshold concentrations, as regulated by 
the Association of Racing Commissioners International (ARCI).44 For example, the regulatory 
threshold concentration for dexamethasone adopted by the ARCI is 0.005 nanograms per 
milliliter (ng/mL), which is equivalent to 5 picograms per milliliter (pg/mL) or 500 femtograms 
per milliliter (fg/mL).44 To put this into perspective, one nanogram is equivalent to 10-9, while 
one picogram is equivalent to 10-12, and one femtogram is equivalent to 10-15. Detection of trace 
levels of therapeutic drugs in animals exhibited at livestock shows is evident by the low levels of 
flunixin detected from 2016 to 2017 (Figure 3, Chapter II). Prior to 2015, TVMDL screened 
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samples from exhibition animals for therapeutic drugs, like flunixin, using either thin layer 
chromatography (TLC) or enzyme-linked immunosorbent assay (ELISA). The limit of detection 
(LOD) for flunixin in urine using these test methods was 250 ng/mL and 2 ng/mL, respectively. 
In 2015, TVMDL transitioned the screening of ante-mortem samples from exhibition animals to 
liquid chromatography – high-resolution accurate mass spectrometry (LC-HRAMS). As a result, 
the LOD for flunixin improved to 0.05 ng/mL, a 40-fold difference. 
Detection of trace levels of therapeutic drugs in animals exhibited at livestock shows 
raises 2 main concerns. The first concern relates to the degree to which very low levels of 
therapeutic drugs provide a performance-enhancing effect in the animal. Animals exhibited at 
livestock shows are unique compared to other performance animals, as they compete based on 
appearance rather than physical activity. Therefore, drugs used in exhibition animals to enhance 
performance do so by altering appearance, such as masking pain, lameness, or inflammation, and 
improving leanness and muscling. Determining the HNED of a drug used to alter the appearance 
of an exhibition animal is challenging compared to drugs that are used to alter activity. For 
example, physiologic responses to exercise can be measured in horses, thus determining a drug’s 
effects on performance potential. Pharmacodynamic (PD) end-points such as heart rate,91 plasma 
lactate concentration,91,92 oxygen uptake level,91 and stride length91,93 are some of the physiologic 
parameters that indicate therapeutic effect of drugs in horses. In addition to lack of ability to 
detect physical effects of drugs in the context of exhibited livestock, researchers have 
demonstrated that untreated animals can have detectable levels of therapeutic drugs, like 
flunixin, from exposure to the drug in the environment. Comingling of treated and untreated 
horses23 and pigs8 resulted in detectable levels of drugs like flunixin in the untreated animals. 
The ARCI has adopted regulatory decision limits for some substances, like caffeine and 
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theobromine, because they are commonly found in the environment and can possibly 
contaminate feed or water.44 
The second concern with “zero tolerance” when regulating therapeutic drugs that are 
legally administered is predicting a withdrawal time in urine or plasma to avoid detection of 
drug. Veterinarians who administer therapeutic drugs to exhibition animals in a legal manner 
face uncertainty when estimating the appropriate amount of time for drug elimination prior to 
competition. If exhibition animals are not to be deprived of proper veterinary care, suitable 
information on the time after administration that therapeutic agents may be detected must be 
made available to the veterinary profession. While urine and plasma withdrawal times for 
flunixin and meloxicam in goats have been estimated (see Chapters III and IV), there is a need 
for a general approach to establishing decision limits for therapeutic drugs used in animals 
exhibited at livestock shows, similar to what is done for horse racing.44  
Increased sensitivity achieved by current analytical techniques allows the detection of 
plasma or urine concentrations of therapeutic drugs for extended periods (i.e., days or weeks) 
after their administration, at which time there is likely no performance-enhancing effect to the 
animal.25 Some researchers estimate negligible drug concentrations with regard to therapeutic 
effects occur after 494 to 5 plasma half-lives.47 Decision limits, drug concentrations at which 
negligible therapeutic effects occur, can be used by testing laboratories to classify samples as 
negative or positive, rather than testing at the LOD for each drug, or a “zero tolerance” approach. 
Additionally, decision limits for therapeutic drugs can also help alleviate the concerns 
surrounding a positive test resulting from environmental contamination.  
Regulation of drugs detected in animals exhibited at livestock shows can be divided into 
2 categories: 1) prohibited substances, and 2) drugs that are administered in a legal manner. 
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While “zero tolerance” is appropriate for prohibited substances, decision limits should be 
established for the latter. The objective of this chapter is to integrate observed and published 
data, PK/PD concepts, and measurement error to propose a method for establishing decision 
limits for therapeutic drugs detected in animals exhibited at livestock shows. To the authors’ 
knowledge, this is the first attempt to establish decision limits for therapeutic drugs detected in 
ante-mortem samples from animals exhibited at livestock shows. 
Consideration of Alternatives 
 Selection of an appropriate method for establishing decision limits for therapeutic drugs 
detected in animals exhibited at livestock shows involves several factors. First, pharmacokinetics 
(PK) are required to characterize the time course of drug absorption and disposition. Second, 
pharmacodynamics (PD) are important as they provide information pertaining to drug effect in 
the animal. Third, it is important to take into consideration tolerances and withdrawal 
information for drug residues in tissue. Last, decision limits for therapeutic drugs must be 
determined for each animal species, and will likely differ among species. This adds a level of 
complexity for testing laboratories as they will need to adapt analytical testing methods and data 
review processes to account for these inter-species differences in thresholds. Here, we consider 3 
different methods for establishing decision limits for therapeutic drugs detected in exhibition 
animals: 1) the 95/95 tolerance interval (TI)95 used in the US by the Racing Medication & 
Testing Consortium (RMTC) Scientific Advisory Committee (SAC); 2) the irrelevant plasma 
concentration (IPC) and irrelevant urine concentration (IUC)96 approach used by regulators in 
horse racing in Europe; and, 3) a novel approach integrating pharmacokinetics and 
pharmacodynamics, including predicted drug effects based on the sigmoidal Emax model using 
the Hill equation. 
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95/95 Tolerance Interval (TI) 
The first method considered for establishing decision limits in therapeutic drugs detected 
in animals exhibited at livestock shows was the 95/95 Tolerance Interval95 used in the US by the 
Racing Medication & Testing Consortium (RMTC) Scientific Advisory Committee (SAC). This 
approach involves the natural logarithmic (ln)-transformation of the normalized mean plasma 
drug concentration measured at a pre-determined withdrawal interval, and a mathematical 
constant ‘K factor’ that is based on the number of animals in the study. 
95/95 Tolerance Interval (TI) calculation equation: 
Meanln + (SDln x K factor) = 95/95 TI, 
where Meanln is the natural logarithm (ln)-transformed mean plasma concentration at a pre-
determined withdrawal interval, and SDln is ln-transformed standard deviation of the plasma 
concentrations at the same pre-determined withdrawal interval. The purpose of the K factor is to 
prevent the ‘oversimplification’ that can result from attributing too much importance to values 
from a limited subset of a population. The European Agency for the Evaluation of Medicinal 
Products’ table of K factors used by the RMTC is presented in Table 12. 
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n K 
2 26.260 
3 7.656 
4 5.144 
5 4.210 
6 3.711 
7 3.401 
8 3.188 
9 3.032 
10 2.911 
11 2.815 
12 2.736 
13 2.670 
14 2.614 
15 2.566 
16 2.523 
17 2.486 
18 2.453 
19 2.423 
20 2.396 
 
Table 12 European Agency for the Evaluation of Medicinal Products’ table of K factors. [n = 
sample size number and K = mathematical constant based on n]95 
 
Determination of the 95/95 TI is made after establishing an appropriate withdrawal 
interval. In horse racing, the RMTC SAC determines an appropriate withdrawal interval based 
on review of the scientific literature and conventional racetrack applications, investigation of any 
illicit use, and consideration of a medication’s potential to affect performance.95 The committee 
then reviews the data from the study horses’ samples collected at that time-point, and applies the 
95/95 TI to establish a regulatory threshold.  
The 95/95 TI method was applied to the flunixin data obtained in Chapter III and results 
are presented in Table 13. For demonstration purposes, withdrawal intervals of 36 hours and 96 
hours were applied to plasma and urine, respectively. 
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 Sample 
Matrix 
Withdrawal 
Interval 
Highest Observed 
Concentration (ng/mL) 
95/95 TI 
(ng/mL) 
Proposed 
Decision Limit 
(ng/mL) 
Plasma 36 HR 19 123 130 
Urine 96 HR 1,109 8,459 8,460 
 
Table 13 95/95 Tolerance Interval (TI) for flunixin in goat plasma and urine using a withdrawal 
interval of 36 hours (plasma) and 96 hours (urine) following intramuscular drug administration. 
 
The margin of safety associated with the ln-transformation of the data and the K factor is 
quite large. At a 36-hour withdrawal interval, the highest flunixin concentration observed in 
plasma was 19 ng/mL. The calculated 95/95 TI based on a 36-hour withdrawal interval is 123 
ng/mL. Rounding to the next largest 10, a proposed threshold for flunixin detected in plasma 
from goats administered flunixin at a dose of 2.2 mg/kg (IM), at a withdrawal interval of 36 
hours, is 130 ng/mL. At a 96-hour withdrawal interval, the highest flunixin concentration 
observed in urine was 1,109 ng/mL. The calculated 95/95 TI based on a 96-hour withdrawal 
interval is 8,459 ng/mL. Rounding to the next largest 10, a proposed threshold for flunixin 
detected in urine from goats administered flunixin at a dose of 2.2 mg/kg (IM), at a withdrawal 
interval of 96 hours, is 8,460 ng/mL. 
The 95/95 TI method was also applied to the meloxicam data obtained in Chapter IV and 
results are presented in Table 14. Similar to flunixin, withdrawal intervals of 36 hours and 96 
hours were applied to plasma and urine, respectively. 
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Sample 
Matrix 
Withdrawal 
Interval 
Highest Observed 
Concentration (ng/mL) 
95/95 TI 
(ng/mL) 
Proposed 
Decision Limit 
(ng/mL) 
Plasma 36 HR 365 1,578 1,580 
Urine 96 HR 36 279 280 
 
Table 14 95/95 Tolerance Interval (TI) for meloxicam in goat plasma and urine using a 
withdrawal interval of 36 hours (plasma) and 96 hours (urine) following oral drug 
administration. 
 
At a 36-hour withdrawal interval, the highest meloxicam concentration observed in 
plasma was 365 ng/mL. The calculated 95/95 TI based on a 36-hour withdrawal interval is 1,578 
ng/mL. Rounding to the next largest 10, a proposed threshold for meloxicam detected in plasma 
from goats administered meloxicam at a dose of 0.5 mg/kg (PO), at a withdrawal interval of 36 
hours, is 1,580 ng/mL. At a 96-hour withdrawal interval, the highest meloxicam concentration 
observed in urine was 36 ng/mL. The calculated 95/95 TI based on a 96-hour withdrawal interval 
is 279 ng/mL. Rounding to the next largest 10, a proposed threshold for meloxicam detected in 
urine from goats administered meloxicam at a dose of 0.5 mg/kg (PO), at a withdrawal interval 
of 96 hours, is 280 ng/mL. 
Advantages and Disadvantages 
One of the advantages in using the 95/95 TI to establish decision limits for therapeutic 
drugs detected in animals exhibited at livestock shows is that it allows for a large margin of 
safety. However, the margin of safety associated with determining the 95/95 TI is largely 
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affected by the sample size. A larger sample size results in a lower K factor. Determination of 
the 95/95 TI above included 5 animals for flunixin in plasma and 4 animals for flunixin in urine 
(Table 13), and 6 animals for meloxicam in plasma and 5 animals for meloxicam in urine (Table 
14). It is likely the 95/95 TI presented in Table 13 and Table 14 would be lower had there been 
more animals in the studies performed in Chapters III and IV. Conversely, studies that based 
thresholds and decision limits by this or any other method that use small sample sizes are 
problematic. 
Another advantage of using the 95/95 TI to establish decision limits is it provides 
veterinarians with a withdrawal interval. This withdrawal interval will allow a veterinarian to 
treat an exhibition animal without fear of generating a positive test result at a show or fair from 
unintended consequences. However, determining an appropriate withdrawal interval for 
therapeutic drugs in plasma and urine from exhibition animal species is quite daunting. First, the 
criteria used by the RMTC SAC in determining an appropriate withdrawal interval are not 
available to livestock show regulators. Information pertaining to a medication’s potential to 
affect performance in an exhibition animal is difficult to measure and not well described in the 
scientific literature. Second, unlike horseracing, there is no governing regulatory body for the 
livestock show industry in the US. The board of directors of the individual show or fair makes 
policies and decisions regarding drug use. Therefore, it will be challenging for all shows and 
fairs to come to an agreement on appropriate withdrawal intervals.  
Last, implementation of the 95/95 TI to establish a decision limit requires standardization 
of the dose and route of administration. Standardization of the dose and route of administration 
may be appropriate for drugs used in a labeled manner. However, this will certainly be 
challenging for drugs used in an extra-label manner, like flunixin in sheep and goats. 
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Irrelevant Plasma Concentration/Irrelevant Urine Concentration (IPC/IUC) 
 The second method considered for establishing decision limits in therapeutic drugs 
detected in animals exhibited at livestock shows was the irrelevant plasma concentration (IPC) 
and irrelevant urine concentration (IUC)96 approach used by regulators in horse racing in Europe. 
Computation of the IPC and IUC involved the following steps96: 
1. Calculation of an effective plasma concentration (EPC), which takes into consideration 
the standard dose (per dosing interval), the bioavailability factor, and the plasma 
clearance (per dosing interval), where F is the bioavailability factor lying between 0 and 
1. Typically the EPC is calculated using intravenous data only so that F = 1, as the EPC is 
the same regardless of route of drug administration. 
𝐸𝐸𝐸𝐸𝐶𝐶 =  𝑠𝑠𝑡𝑡𝑅𝑅𝑅𝑅𝑡𝑡𝑅𝑅𝐶𝐶𝑡𝑡 𝑡𝑡𝑑𝑑𝑠𝑠𝑅𝑅 (𝑝𝑝𝑅𝑅𝐶𝐶 𝑡𝑡𝑑𝑑𝑠𝑠𝑑𝑑𝑅𝑅𝑑𝑑 𝑑𝑑𝑅𝑅𝑡𝑡𝑅𝑅𝐶𝐶𝑖𝑖𝑅𝑅𝑅𝑅)𝑥𝑥 𝐹𝐹
𝑝𝑝𝑅𝑅𝑅𝑅𝑠𝑠𝑚𝑚𝑅𝑅 𝐶𝐶𝑅𝑅𝑅𝑅𝑅𝑅𝐶𝐶𝑅𝑅𝑅𝑅𝐶𝐶𝑅𝑅 (𝑝𝑝𝑅𝑅𝐶𝐶 𝑡𝑡𝑑𝑑𝑠𝑠𝑑𝑑𝑅𝑅𝑑𝑑 𝑑𝑑𝑅𝑅𝑡𝑡𝑅𝑅𝐶𝐶𝑖𝑖𝑅𝑅𝑅𝑅) 
2. Calculation of the IPC, which is made by dividing the EPC by a safety factor (SF). The 
selection of an SF is mainly a subjective choice of regulatory officials. 
𝐼𝐼𝐸𝐸𝐶𝐶 =  𝐸𝐸𝐸𝐸𝐶𝐶 𝑆𝑆𝐹𝐹⁄ . 
A default SF of 500 (i.e., 10 x 50) is commonly used, with 50 to transform an effective 
plasma concentration close to EC50 into an ineffective one, and 10 to take inter-individual 
variability into account.97  
3. The IUC is calculated by multiplying the IPC by the steady-state urine to plasma 
concentration ratio (Rss). 
𝐼𝐼𝐴𝐴𝐶𝐶 = 𝐼𝐼𝐸𝐸𝐶𝐶 × 𝑅𝑅𝑠𝑠𝑠𝑠. 
4. Checking the appropriateness of IPC and IUC. The appropriateness of the IPC and IUC 
are determined by computing the amount of drug remaining in the body when the plasma 
concentration is equal to the IPC and by calculating the shortest possible withdrawal time 
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(WT) of the drug. The residual amount (RA) of drug in the body when plasma 
concentration is equal to the IPC is given by the following equation: 
𝑅𝑅𝐴𝐴 = 𝐼𝐼𝐸𝐸𝐶𝐶 × 𝑉𝑉𝑅𝑅𝐶𝐶𝑅𝑅𝑅𝑅, 
where Varea is the volume of distribution calculated by the area method. This RA can 
then be compared to the recommended dosage regimen and should be lower than a given 
percentage of the recommended dose (e.g., 1%). 
 Results of applying the IPC/IUC method using the flunixin and meloxicam data obtained 
in Chapters III and IV are presented in Table 15 and Table 16, respectively. 
 
EPC (ng/mL) IPC (ng/mL) IUC (ng/mL) 
610 1.2 17.7 
 
Table 15 Effective plasma concentration (EPC), irrelevant plasma concentration (IPC) and 
irrelevant urine concentration (IUC) for flunixin in goats following intramuscular administration 
(2.2 mg/kg). 
 
EPC (ng/mL) IPC (ng/mL) IUC (ng/mL) 
305 0.6 0.8 
 
Table 16 Effective plasma concentration (EPC), irrelevant plasma concentration (IPC) and 
irrelevant urine concentration (IUC) for meloxicam in goats following oral administration (0.5 
mg/kg). 
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Determination of the EPC utilizes a bioavailability factor (F) that lies between 0 and 1. In 
most cases, the EPC is calculated using intravenous data so that F = 1, as the EPC is the same 
regardless of the route of drug administration.96 Even though the flunixin and meloxicam data 
obtained were not from intravenous drug administration, an F of 1 was still applied when 
calculating the EPC. Applying an SF of 500 resulted in an IPC of 1.2 ng/mL and IUC of 17.7 
ng/mL for flunixin, and an IPC of 0.6 ng/mL and IUC of 0.8 ng/mL for meloxicam. The mean 
Rss was determined using the urine and plasma drug concentrations at the elimination half-life 
for each goat. The Rss for flunixin was determined to be 14.4 and the Rss for meloxicam was 
determined to be 1.3. The RA for flunixin was 1.0 µg/kg, which is below 0.05% of the 
recommended dose. The RA for meloxicam was 0.32 µg/kg, which is below 0.1% of the 
recommended dose. 
When comparing the flunixin concentrations in urine presented in Figure 3 (Chapter II) to 
the IUC for flunixin in Table 15 above, one can see the effectiveness of IPC/IUC in establishing 
a decision limit for flunixin. Out of the 25 animals with quantified flunixin concentrations, 18 
were below the IUC of 17 ng/mL. Although the animal species for those values presented in 
Figure 3 (Chapter II) were not solely goats, a decision limit of 17 ng/mL would have resulted in 
a negative test result for more than 70% of those animals.  
Advantages and Disadvantages 
Determination of the IPC and IUC involves plasma clearance, and determination of 
plasma clearance depends on route of drug administration. One advantage of the IPC/IUC 
method is its independence from route of administration (providing its action is systemic).96 
However, the IPC/IUC method also relies on the assumption that drug effects are reversibly 
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driven by the plasma concentration profile, and cannot be used for drugs whose effects last long 
after the drug has been eliminated (e.g., corticosteroids and anabolic steroids).96 
Another advantage of using the IPC/IUC method to establish thresholds for therapeutic 
drugs detected in exhibition animals is that it does not involve a withdrawal interval such that it 
may be more practicable than the 95/95 TI method to establish decision limits for therapeutic 
drugs detected in animals exhibited at livestock shows. Another advantage of using the IPC/IUC 
method to establish decision limits for therapeutic drugs detected in animals exhibited at 
livestock shows is PK data, such as plasma clearance, used to calculate EPC is readily obtainable 
from the scientific literature for various exhibition animal species. 
A disadvantage of using the IPC/IUC method to establish decision limits for therapeutic 
drugs detected in exhibited livestock is that this method does not account for a withdrawal 
interval. Veterinarians face challenges when administering therapeutic drugs to exhibition 
animals as some drugs are detected in urine after the labeled meat withdrawal time. Using the 
IPC/IUC method does not provide veterinarians with a withdrawal interval to avoid an adverse 
analytical finding in urine, from unintentional consequences.  
Another disadvantage of this method is that IUC requires knowing the urine to plasma 
concentration ratio (Rss), which is seldom reported in the scientific literature. Consequently, the 
Rss must be approximated from published raw data or from published figures, and these may not 
always be available/accessible. 
Sigmoidal Emax Model Using the Hill Equation 
One of the challenges when therapeutic drugs are detected in urine from animals 
exhibited at livestock shows is interpreting physiologic or performance-enhancing effects. While 
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it is difficult to measure performance-enhancing effects of therapeutic drugs in food animals, 
determination of decision limits should account for drug effect (PD) in the animal. Therefore, the 
third method we considered for establishing decision limits for therapeutic drugs detected in 
animals exhibited at livestock shows was the Hill equation, also known as the sigmoidal Emax 
model. The Hill equation is often used in PK-PD modeling to construct the dose-response 
relationship between drug effect (often the concentration of some biomarker(s)) and drug 
concentration given by the following equation39,98: 
𝐸𝐸 =  𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚 𝑥𝑥 𝐴𝐴𝑛𝑛
𝐴𝐴𝑛𝑛+ 𝐼𝐼𝐴𝐴50𝑛𝑛 ; 
where E is the drug effect expressed in percentage inhibition, Emax is the maximal inhibitory 
effect, n is the Hill constant, IC50 is the drug concentration producing 50% of the Emax, and C is 
the drug concentration in plasma. 
 Irritation or injury to the body leads to the release of arachidonic acid, which is 
metabolized by enzyme systems leading to the formation of inflammatory mediators termed, 
eicosanoids. Eicosanoids, such as prostaglandins and thromboxanes, are involved in many 
physiological systems, including pain, inflammation, and modulating the regional flow of blood 
to tissues. Cyclooxygenase is the first enzyme in the pathway leading from arachidonic acid to 
prostaglandins and thromboxanes. NSAIDs like flunixin and meloxicam work by blocking 
cyclooxygenase (COX), as depicted in Figure 8 below. 
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Figure 8 Inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) by 
nonsteroidal anti-inflammatory drugs (NSAIDs). 
(https://www.memorangapp.com/flashcards/61816/2.10+-+Anti-Inflammatory+Drugs/)  
 
The inhibiting effects of COX isoenzymes by NSAIDs has been demonstrated by 
measuring serum thromboxane (TXB2) concentrations generated by platelets in clotting blood 
(COX-1),39-42,81,99-105 by measuring exudate prostaglandin E2 (PGE2) concentrations generated by 
carrageenan-induced inflammation in the subcutaneous tissue-cage (COX-2),39,41,42,81,105 and by 
measuring plasma PGE2 concentrations.99-101  
Drug concentrations in plasma, at which inhibitory effects of biomarkers from NSAIDs 
exposure occur were evaluated as possible decision limits for animals exhibited at livestock 
shows. While concentrations of flunixin and meloxicam resulting in the inhibition of PGE2 have 
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been measured in exudate, it is difficult to correlate exudate and plasma concentrations.  
Additionally, flunixin and meloxicam concentrations resulting in the inhibition of PGE2 have 
been measured in equine100 and feline plasma,101 but these concentrations cannot be extrapolated 
to other animal species. Therefore, evaluation of the Hill equation as a method for establishing 
decision limits for therapeutic drugs detected in animals exhibited at livestock shows was based 
on published TXB2 data.  
Inhibition of TXB2 from flunixin administration has been evaluated in multiple animal 
species. Plasma flunixin concentrations (ng/mL) that produced 50% of the maximal effect (IC50) 
in different animal species are presented in Table 17. IC50 data for inhibition of TXB2 from 
meloxicam administration were not available.  
 
Species Dose Route of Administration IC50 (ng/mL) 
Ovine 1.1 mg/kg IV 5.04 ± 3.3 
Caprine 0.3 – 60 ng/mL in vitro 5.93 
Bovine 2.2 mg/kg IV 24 ± 4 
Equine 0.3 – 60 ng/mL in vitro 11.85 
Canine 0.3 – 60 ng/mL in vitro 29.62 
 
Table 17 Effect of flunixin meglumine on serum thromboxane (TXB2). IC50 = plasma drug 
concentration which produced 50% of the maximal effect. IV = intravenous 
  
Establishing decision limits for therapeutic drugs in exhibition animals should take into 
consideration the drug concentration that produces minimal effect in the animal. For example, 
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the decision limit should be based on the IC10, the drug concentration producing 10% of the 
maximal effect, as opposed to the IC50. Calculation of the IC10 can be performed using the 
following equation106: 
𝐼𝐼𝐶𝐶𝐹𝐹 = � 𝐹𝐹100−𝐹𝐹�√𝑛𝑛  𝑥𝑥 𝐼𝐼𝐶𝐶50 ; 
where F is the % response, n is the Hill constant, and IC50 is the drug concentration producing 
50% of the maximal response. The IC10 concentrations in sheep, goats, and cattle were calculated 
using the IC50 values presented in Table 17 and a Hill constant of 1. The IC10 concentrations 
were determined to be 0.56, 0.66, and 2.67 ng/mL for sheep, goats, and cattle, respectively. It 
was not possible to determine a confidence interval for the IC10 concentrations due to the limited 
data available. Therefore, a safety factor of 10 was applied to account for the variability in 
determining these concentrations. With a safety factor of 10, the IC10 concentrations were 
determined to be 0.056, 0.066, and 0.267 ng/mL in sheep, goats, and cattle, respectively. It is 
important to note that these low flunixin concentrations are near the LOD of the analytical test 
method. This indicates the effect of flunixin on TXB2 likely persists after the drug is no longer 
detectable in plasma, as previously reported.39 
 Determination of a withdrawal interval can also be made by determining the time at 
which minimal drug effect occurs. For example, IT50, the time at which a drug produces 50% of 
the maximal effect can be calculated from the sigmoidal inhibitory effect model using the Hill 
Equation39: 
𝐸𝐸 = 𝐸𝐸𝑚𝑚𝑚𝑚𝑥𝑥 −  𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚 𝑥𝑥 𝑇𝑇𝑛𝑛𝑇𝑇𝑛𝑛+ 𝐼𝐼𝑇𝑇50𝑛𝑛 ; 
where E is the drug effect expressed in percentage inhibition, Emax is the maximal inhibitory 
effect, n is the Hill constant, T is the time, and IT50 is the time at which the drug effect declines 
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by 50%. Subsequently, the IT90, the time at which the drug effect declines by 90%, can be 
performed using the following equation106: 
𝐼𝐼𝐼𝐼𝐹𝐹 = � 𝐹𝐹100−𝐹𝐹�√𝑛𝑛  𝑥𝑥 𝐼𝐼𝐼𝐼50 ; 
where F is the % response, n is the Hill constant, and IT50 is the time at which the drug effect 
declines by 50%. The IT50 for TXB2 inhibition following intravenous flunixin administration was 
reported in sheep (29 ± 1.9 hours).39 Using the equation above, IT90 for TXB2 inhibition 
following intravenous flunixin administration in sheep was determined to be 46.8 hours. After 
rounding this number to 48 hours, a safety factor of 12 hours can be applied. Therefore, an 
appropriate withdrawal interval to achieve an IC10 of TXB2 inhibition following intravenous 
flunixin administration in sheep is 60 hours. IT50 was not reported in other species. 
Advantages and Disadvantages 
One advantage with the sigmoidal Emax model using the Hill Equation to establish 
decision limits for therapeutic drugs detected in animals exhibited at livestock shows is the fact 
that decision limits are based on pharmacodynamics. The other 2 methods do not take into 
consideration drug effect in the animal. This makes the sigmoidal Emax model using the Hill 
Equation a more desirable approach to establish decision limits. 
One disadvantage with using the Hill equation as a model to establish decision limits for 
therapeutic drugs detected in animals exhibited at livestock shows is correlating IC50 and IC10 
between plasma and urine. Most shows collect urine for drug testing exhibition animals such that 
decision limits for therapeutic drugs detected in urine based on the Hill equation must be 
obtained using plasma data. In the case of flunixin, inhibition of TXB2 likely persists after the 
drug is no longer detectable in plasma, which creates even more of a challenge when trying to 
correlate plasma and urine drug concentrations.  
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Another limitation with the sigmoidal Emax model using the Hill Equation is that there are 
currently data gaps that will delay implementation of this approach. While IC50 inhibition of 
serum TXB2 concentrations from flunixin administration has been measured in most food animal 
species, plasma PGE2 concentrations have not. PGE2 correlates better with the performance-
enhancing effects (COX-2) flunixin has in exhibition animals than TXB2, and is therefore a more 
applicable biomarker. Additional studies will need to be performed in food animal species to 
determine IC50 inhibition of plasma PGE2 from flunixin administration. Another data gap that 
exists with the sigmoidal Emax model using the Hill Equation is lack of information for IT50 
associated with plasma TXB2 and plasma PGE2 in cattle, sheep, goats, and pigs. Determination 
of IT50 is necessary to establish withdrawal intervals for plasma and urine. 
Measurement Uncertainty 
 Establishing decision limits for therapeutic drugs detected in exhibition animals will 
require a change in how analytical testing is performed for livestock shows. Currently, test 
results are reported qualitatively (e.g., positive or negative). Implementing decision limits will 
require the testing laboratory to perform quantitative testing, determining the concentration of 
the drug in the sample, and then forming a conclusion by comparing the measured concentration 
to the decision limit. Determining the uncertainty associated with the analytical assay and 
measured drug concentration will be critical in determining whether a sample is positive or 
negative. Uncertainty is an interval associated with a measurement result that expresses the range 
of values that can reasonably be attributed to the quantity being measured.107 Uncertainty is a 
basic characteristic of any measurement and is always present, at every step of a procedure.108  
Analytical testing laboratories determine measurement uncertainty during method 
validation. The first stage of determining the measurement uncertainty is to identify the sources 
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of uncertainty for the method. There are a number of possible sources of uncertainty in 
measurement that are not only introduced by the analytical equipment and test methods, but also 
by the person performing the test, data analysis, and the environment. Some of these sources 
include purity of reagents, sampling, measurement conditions, sample effects, computational 
effects, and random effects.109,110 Random error, errors that fluctuate due to the unpredictability 
or uncertainty inherent in the measuring process, affect precision. Systematic error, errors 
associated with incorrect equipment calibration or a flawed experimental design, affect the 
validity of the measurements and cause bias. Once the sources of uncertainty have been 
identified they require evaluation, which is done by determining the ruggedness and precision of 
the method by performing recovery studies. Finally, once the individual uncertainty components 
for the method have been calculated, they must be combined to give standard and expanded 
uncertainties for the method as a whole.110 
In analytical testing for drugs and chemicals, the standard uncertainty can be evaluated 
from the dispersion of repeated measurements and calculated using the standard deviation of the 
mean111: 
𝑆𝑆𝑋𝑋 =  𝑆𝑆√𝑛𝑛 ; 
where111: 
𝑆𝑆 =  �∑ (𝑥𝑥𝑖𝑖− 𝑥𝑥)2𝑛𝑛𝑖𝑖=1
𝑛𝑛−1
 ; 
then the expanded uncertainty can be determined by multiplying the standard uncertainty by the 
chosen coverage factor, k. For most purposes, k is set to 2. However, if the standard uncertainty 
is based on statistical observations with relatively few degrees of freedom (less than about six), k 
is equal to the two-sided value of Student’s t for the number of degrees of freedom and the level 
of confidence (normally 95%).111 Finally, the result is reported as: 
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Result = x ± uncertainty (units). 
For illustration purposes, let us assume the method validation for flunixin in urine included 
twenty individual negative urine aliquots spiked at a concentration of 20 ng/mL. Quantitative 
values for each aliquot were obtained by measuring against a calibration curve that consisted of 
the following calibrators spiked in urine: 5 ng/mL, 10 ng/mL, 15 ng/mL, 20 ng/mL, 25 ng/mL, 
and 40 ng/mL. The mean was 19.865 ng/mL and population standard deviation (S) was 9.57. The 
standard deviation of the mean taken from the population (𝑆𝑆𝑋𝑋 ) was 2.14. When multiplying by a 
k of 2 (95% confidence interval), the expanded uncertainty was 4.3 ng/mL. For illustration 
purposes, let us assume the threshold for flunixin in urine is 20 ng/mL. Therefore, when taking 
into consideration the uncertainty of the validated method, a sample concentration below 24.3 
ng/mL would be considered below the decision limit. 
 While variability exists in measuring drug concentrations in biological samples, there are 
also sources of variability when assessing pharmacokinetic and pharmacodynamic parameters in 
animal populations. Sources of variability when performing PK/PD analyses can include breed, 
disease, age, gender, weight, drugs given concomitantly, and various behavioral and 
environmental factors.47,112 Population pharmacokinetics is used to study how a drug varies in 
patients who are representative of the target population to be treated with the drug.113,114 
Population pharmacokinetics is being increasingly used in drug development to assess drug 
safety and efficacy, and thus is usually performed in a relatively large number of patients. Non-
population pharmacokinetic studies are usually carried out in small numbers of healthy animals, 
which can create challenges in predicting drug disposition in animals that are sick. However, 
unlike population pharmacokinetics, non-population pharmacokinetics does not allow for 
screening and quantification of covariates for explaining variability. Therefore, it may be 
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necessary to apply a safety factor to account for variability that is difficult to extrapolate or 
measure. For example, determination of tolerances for edible tissues by the FDA Center for 
Veterinary Medicine involves toxicology studies that are performed to determine the acceptable 
daily intake (ADI) of residues in edible tissues. The ADI is based on the highest dose of a drug 
that produces no observable effects, which can be a no-observed-effect level (NOEL) or a no-
observed-adverse-effect level (NOAEL). A safety factor, which reflects uncertainties associated 
with the extrapolation of data and information from toxicology studies to humans, of 100 is then 
applied.54 
Regulatory Decision Making 
Unlike the horse racing industry, there is no central regulatory body to create policies and 
provide guidance on drug testing in exhibition animals. Therefore, each show creates and 
enforces their own rules. This creates challenges for exhibitors as they must be familiar with and 
adapt to a different set of rules as they travel from show to show. This also creates challenges for 
veterinarians as one show may allow a certain drug to be in an animal’s system during exhibition 
while another does not. For example, flunixin is regulated by most shows with a “zero tolerance” 
policy. However, some shows allow flunixin to be in an animal’s system during the exhibition. 
Another challenge with regard to regulating drug testing in exhibition animals is the lack 
of standardization in testing. Each laboratory performs drug testing using different extraction 
procedures, equipment, test methods, and instrument methods. Therefore, detection of drugs in 
exhibition animals can vary among laboratories. Some laboratories have equipment that offer 
remarkable sensitivity, while others use less sensitive testing methods or instruments. Testing at 
the limit of detection of the analytical assay can cause discrepancies in test results between 
laboratories. For example, it is possible for a drug to be detected in an animal by one laboratory, 
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but not detected in that animal by another laboratory. As a result, the test method employed must 
be considered when comparing test results between 2 independent laboratories from the same 
animal. 
Establishing decision limits for therapeutic drugs detected in animals exhibited at 
livestock shows will create some standardization in the livestock show industry. For example, 
decision limits will create uniformity in how laboratories distinguish between a positive and 
negative sample, regardless of differences in extraction procedures, equipment, test methods, and 
instrument methods. Additionally, livestock shows and fairs are more likely to standardize drug 
testing policies with the implementation of decision limits that are based on scientific data. 
Based on the data presented in Chapter II and described throughout, flunixin presents the 
greatest need for establishing a regulatory decision limit. However, other therapeutic drugs, such 
as meloxicam are used in exhibited livestock and these drugs also will require attention from 
livestock show regulators for establishing decision limits. Other therapeutic drugs used and 
detected in exhibition animals that should be considered and evaluated include phenylbutazone, 
dexamethasone, acetaminophen, lidocaine, isoflupredone, methylprednisolone, firocoxib, and 
ketoprofen. Some of these drugs are NSAIDs and potential pharmacodynamic biomarkers have 
been identified and described. However, a review of the scientific literature to identify potential 
PD biomarkers is necessary for those drugs that are not NSAIDs. 
Conclusions 
The 95/95 TI method is based on a withdrawal interval that is agreed upon by the 
regulatory body. In horseracing, determination of this withdrawal interval takes into 
consideration the amount of time that must pass to achieve negligible performance-enhancing 
effects in the animal. However, it is difficult to gauge when such an interval occurs in food 
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animal species, particularly when assessing drug concentrations in urine. If livestock show 
regulators decide plasma is a more viable sample to test for therapeutic drugs in exhibition 
animals, perhaps the 95/95 TI can be applied as it will be easier to determine an appropriate 
withdrawal interval in plasma. 
The IPC/IUC method presents a challenge for livestock show regulators as it does not 
take into consideration performance-enhancing effects in the animal and will require the 
determination of a safety factor agreed upon by all livestock shows. This method also has 
limitations in that it cannot be used for drugs whose effects last long after the drug has been 
eliminated. 
Using the Hill equation to establish decision limits for therapeutic drugs detected in 
exhibition animals provides a logical approach as it accounts for drug effect in the animal. 
Application of this method for flunixin as described above was solely based on inhibition of 
TXB2. However, inhibition of PGE2 also occurs and thus additional studies are warranted in food 
animal species to determine IC50 for PGE2 inhibition prior to making regulatory decision limits. 
As noted above, IC10 values for TXB2 inhibition from flunixin administration were close to the 
LOD of the analytical test method. This suggests that the inhibitory effects of flunixin on TXB2 
likely persist after the drug is no longer detected in plasma. Thus, “zero tolerance” may be a 
valid argument for flunixin detected in plasma. While physiologic inhibition of TXB2 and PGE2 
occur at the IC10, it is unclear if these inhibitory effects result in a performance-altering effect in 
the animal that creates an unfair advantage during competition. 
While one or more of the methods described for establishing decision limits for 
therapeutic drugs detected in animals exhibited at livestock shows may provide a path forward, 
additional data are needed. First, pharmacodynamics using biomarkers allows the measurement 
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of drug effect in the animal. However, it is unclear if detection of these biomarkers at any level 
correlates with a performance-altering effect in an exhibition animal. Also, PGE2 appears to 
correlate more strongly with the desired performance-enhancing effects of NSAIDs in exhibition 
animals than TXB2. Therefore, studies measuring plasma PGE2 levels following NSAID 
administration in cattle, sheep, goats, and pigs are warranted. Evaluation of other biomarkers of 
NSAID exposure for potential implications on altered performance is also recommended. 
Second, it is difficult to correlate drug concentrations in plasma and urine from information 
published in cattle, sheep, goats, and pigs. Data describing detection of drugs in urine over time 
in these species are limited. PK studies, similar to those performed in Chapters III and IV, in 
other animal species are necessary to obtain information on drug disposition in both plasma and 
urine, and to evaluate their correlation. This is especially true if livestock shows are to continue 
regulating doping in exhibition animals by testing urine. Last, establishing decision limits for 
therapeutic drugs detected in exhibition animals should account for pharmacokinetics and 
pharmacodynamics of animals with disease. Exhibition animals requiring treatment for an illness 
prior to a show may have differences in drug disposition and elimination compared to healthy 
animals. PD biomarkers may also behave differently in animals with disease as opposed to 
healthy animals.  
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CHAPTER VI 
CONCLUSIONS 
 
Conclusions 
Improvements in analytical test methods in recent years have called into question the 
appropriateness of current regulation of drug testing in animals exhibited at livestock shows 
using a so-called “zero tolerance” approach. While this policy is appropriate for prohibited 
substances, detection of trace amounts of therapeutic drugs, such as flunixin, used in a legal 
manner has raised concerns within the livestock show industry. First, detection of trace amounts 
of therapeutic drugs in urine raises the question of whether or not performance-enhancing effects 
occur in the animal at these very low concentrations. Second, veterinarians face challenges when 
providing care to exhibition animals, as they are unsure of appropriate withdrawal times for 
therapeutic drugs in urine to avoid an adverse analytical finding from unintended consequences. 
Last, the possibility of environmental contamination from the co-mingling of treated and 
untreated animals has been demonstrated.8,23 Thus, the need to establish decision limits for 
therapeutic drugs detected in animals exhibited at livestock shows is evident. 
 PK studies, like those performed in Chapters III and IV, are necessary to evaluate the 
movement of a drug into, throughout and out of the body; that is, the time-course of the drug’s 
absorption, bioavailability, distribution, metabolism, and excretion.32 Likewise, this information 
is also important when establishing decision limits. Most livestock shows collect urine from 
exhibition animals for drug testing. However, the flunixin PK data presented in Chapter III 
provides an example of the variability of drug concentrations in urine. Urine provides a longer 
detection time for some drugs compared to plasma. While this is advantageous for prohibited 
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substances, this may not be the case for therapeutic drugs. Duration of therapeutic effects 
correlates better with plasma drug concentrations.43-46,81,82 Thus, consideration should be given to 
regulating the use of therapeutic drugs, like flunixin, in animals exhibited at livestock shows 
using plasma as opposed to urine. 
 Three different methods for establishing decision limits for therapeutic drugs detected in 
animals exhibited at livestock shows have been described. The first method, the 95/95 Tolerance 
Interval, is based on a withdrawal interval that is agreed upon by the regulatory body. 
Determination of this withdrawal interval should take into consideration the amount of time that 
must pass to achieve negligible performance-enhancing effects in the animal. This presents a 
challenge for livestock show regulators as it is difficult to gauge when such an interval occurs in 
food animal species, particularly when assessing drug concentrations in urine. The second 
method, the irrelevant plasma concentration (IPC) and irrelevant urine concentration (IUC) is 
based on the standard drug dose and plasma clearance to determine the effective plasma 
concentration. Then the IPC is determined by applying a safety factor, which again is a 
regulatory decision. Last, the IUC is obtained by multiplying the IPC by the steady-state urine to 
plasma concentration ratio. The IPC/IUC method presents a challenge for livestock show 
regulators as it does not take into consideration performance-enhancing effects in the animal and 
will require the determination of a standardized safety factor. The third method described for 
establishing decision limits for therapeutic drugs detected in animals exhibited at livestock shows 
was the sigmoidal Emax model using the Hill equation to determine the IC10, the drug 
concentration producing 10% of the maximal effect. This method also allows for the 
determination of the IT90, the time at which the drug effect declines by 90%. While this method 
takes into consideration physiologic effects produced by a drug, it was not possible to apply 
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limits derived from plasma data to data from urine, which is all that is available for exhibited 
livestock.  
Should livestock show regulators decide to test for therapeutic drugs in plasma rather 
than urine, the author recommends establishing decision limits that combine 2 of the methods 
described in Chapter V. First, the drug concentration that produces minimal effect in the animal 
should be determined (e.g., IC10). Then the time to reach this concentration (e.g., IT90) should be 
calculated. Finally, the 95/95 TI method can be performed using this withdrawal interval to 
determine the regulatory threshold and subsequent decision limit. 
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